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                                 I.INTRODUCTION    
I.1.1 CANCER (1),    
The division of normal cell is precisely controlled.new cells are only formed for 
growth or to replace dead ones. Cancerous cells divide repeatedly out of control even 
though they are not needed, they crowd out other normal cells and function 
abnormally .they can also destroy the correct functioning of major organs 
 Benign tumours do not spread from their site of origin, but can crowd out 
(squash)   surrounding cells eg brain tumour, warts. 
 Malignant tumours can spread from the original site and cause secondary 
tumours. This is called metastasis. They interfere with neighbouring cells 
and can block blood vessels, the gut, glands, lungs etc. 
Neoplasia literally means the process of "new growth," and a new growth is 
called a neoplasm. The term tumor was originally applied to the swelling caused by 
inflammation. Neoplasms also may induce swellings, but by long precedent, the non-
neoplastic usage of tumor has passed into limbo; thus, the term is now equated with 
neoplasm. Oncology (Greek oncos = tumor) is the study of tumors or neoplasms. 
Cancer is the common term for all malignant tumors. Although the ancient origins of 
this term are somewhat uncertain, it probably derives from the Latin for crab, 
cancer—presumably because a cancer "adheres to any part that it seizes upon in an 
obstinate manner like the crab." 
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I.1.2 TYPES OF CANCERS 
According to conventional allopathic medicine there are over 150 types of cancers 
that can be categorized as follows: 
 carcinomas are cancer that formed in the Lung, breast, prostate, skin, 
stomach, and colon and    are characterized by solid tumors. 
 Sarcomas are cancers that form in the bone and the soft tissues surrounding 
organs. They are solids and are the most rare and deadly forms of malignant 
tumors. 
 Leukemia forms in the blood and the bone marrow. These are non-solid 
tumors and are characterized by abnormal production of white blood cells. 
 Lymphomas are cancers of the lymph nodes. They are divided into two 
categories, Hodgkin’s and Non-Hodgkin’s. 
 Myelomas are rare tumors that form in the antibodies producing plasma cells 
in various tissues. 
 I.1.3 CAUSES FOR CANCER (2,3) 
 Sunlight 
 Chronic Exposure to Electromagnetic Fields (EMFs) 
 Ionizing Radiation 
 Pesticide/Herbicide Residues 
 Industrial Toxins 
 Polluted, Chlorinated and Fluoridated Water 
 Tobacco 
 Hormone Therapies 
 Wrong Diet and Nutrition 
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 Emotional Stress 
 Intestinal Toxicity and Digestive Impairment 
 Viruses(Hepa,titis B virus Epstein-Barr virus 
 Blocked Detoxification Pathway 
 Cellular Oxygen Deficiency 
 Genetic Factors 
I.1.4 CANCER STAGING (2,3)   
Type of cancer stages 
• In situ 
• Local 
• Regional 
• Distant 
 
Staging tells us the extent of the disease. 
•   Treatment depends on the stage of the specific cancer. 
• Staging helps determine the patient’s prognosis (prediction of course and 
outcome of disease, especially chances of recovery). 
The Stage of  Cancer (2,3) 
This describes how far cancer has spread. It is usually from stage I to IV, and 
often followed by “A” or “B” to further delineate the severity within each stage. In 
general, stage I cancers are small localized cancers that are usually curable, while 
stage IV usually represents inoperable or metastatic cancer. Stage II and III cancers 
are usually locally advanced and/or with involvement of local lymph nodes. It is 
important to note that the staging system is different for each kind of cancer. For solid 
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tumors, stages I-IV are actually defined in terms of a more detailed staging system 
called the “TNM” system. In the TNM system, TNM stands for Tumor, Nodes, and 
Metastases. Each of these is separately classified with a number to give the total stage. 
For example, a T2N1M0 cancer means the patient has a T2 tumor, N1 lymph node 
involvement, and no distant metastases. Again, the definitions of T, N and M are 
specific to each cancer. 
I.1.5 CANCER INCIDENCE  
 In some measure, an individual's likelihood of developing a cancer is 
expressed by national incidence and mortality rates. For example, residents of the 
United States have about a one in five chance of dying of cancer. There were, it is 
estimated, about 556,000 deaths from cancer in 2003, representing 23% of all 
mortality, a frequency surpassed only by deaths caused by cardiovascular diseases. 
These data do not include an additional 1 million, for the most part readily curable, 
non-melanoma cancers of the skin and 100,000 cases of carcinoma in situ, largely of 
the uterine cervix but also of the breast. The major organ sites affected and the 
estimated frequency of cancer deaths are shown. The most common tumors in men 
are prostate, lung, and colorectal cancers. In women, cancers of the breast, lung, and 
colon and rectum are the most frequent. Cancers of the lung, female breast, prostate, 
and colon/rectum constitute more than 50% of cancer diagnoses and cancer deaths in 
the U.S. population. 
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I.1.6 CANCER STATISTICS 
 
      Fig.I.1Cancer statistics  
I.1.7 CANCER EVENT (2,3)  
First, we must understand that cancer-prone events occur in our bodies in clusters. 
These include: 
• Genetic instability in the nucleus 
• Abnormal expression of genes, resulting in too few proteins that 
Inhibit cancer and too many that facilitate it 
• Abnormal cell-to-cell communications 
• Induction of angiogenesis 
• Invasion and metastasis 
• Immune evasion 
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I.1.8 COLO RECTAL CANCER (4) 
Colorectal cancer, commonly known as bowel cancer, is a cancer from 
uncontrolled cell growth in the colon, rectum, or appendix.  
The colon is the part of the digestive system where the waste material is 
stored. The rectum is the end of the colon adjacent to the anus. Together, they form a 
long, muscular tube called the large intestine (also known as the large bowel). Tumors 
of the colon and rectum are growths arising from the inner wall of the large intestine. 
Benign tumors of the large intestine are called polyps. Malignant tumors of the large 
intestine are called cancers. Benign polyps do not invade nearby tissue or spread to 
other parts of the body. Benign polyps can be easily removed during colonoscopy and 
are not life-threatening. If benign polyps are not removed from the large intestine, 
they can become malignant (cancerous) over time. Most of the cancers of the large 
intestine are believed to have developed from polyps. Cancer of the colon and rectum 
(also referred to as colorectal cancer) can invade and damage adjacent tissues and 
organs. Cancer cells can also break away and spread to other parts of the body (such 
as liver and lung) where new tumors form. The spread of colon cancer to distant 
organs is called metastasis of the colon cancer. Once metastasis has occurred in 
colorectal cancer, a complete cure of the cancer is unlikely 
Most colorectal cancer occurs due to lifestyle and increasing age with only a 
minority of cases associated with underlying genetic disorders. It typically starts in 
the lining of the bowel and if left untreated, can grow into the muscle layers 
underneath, and then through the bowel wall. Screening is effective at decreasing the 
chance of dying from colorectal cancer and is recommended starting at the age of 50 
                                                                                   INTRODUCTION                                          
 
Department of Pharmaceutical Chemistry                                                                   Page 7 
 
and continuing until a person is 75 years old. Localized bowel cancer is usually 
diagnosed through sigmoidoscopy or colonoscopy. 
 
Fig.I.2 Colon cancer  
Globally, cancer of the colon and rectum is the third leading cause of cancer in males 
and the fourth leading cause of cancer in females. The frequency of colorectal cancer 
varies around the world. It is common in the Western world and is rare in Asia and 
Africa. In countries where the people have adopted western diets, the incidence of 
colorectal cancer is increasing. 
I.1.9 CAUSES OF COLON CANCER (5) 
• Inflammatory bowel disease (ulcerative colitis and Crohn's disease) 
• primary sclerosing cholangitis 
• High fat content in diet 
• Genetics and colon cancer 
o FAP (familial adenomatous polyposis) 
o AFAP (attenuated familial adenomatous polyposis) 
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o HNPCC (hereditary nonpolyposis colon cancer) 
o MYH polyposis syndrome is a recently discovered hereditary colon 
cancer syndrome 
I.1.10 SYMPTOMS 
Colo –rectal cancer symptoms come in two general varieties: 
  1. Local 
  2. Systemic 
Local Colo-rectal Cancer Symptoms 
    * Changes in your bowel habits, 
    * Constipation  
    * Diarrhea 
    * Intermittent  
    * Bright red or dark red blood in your stools  
    * Stools that are thinner than normal ("pencil stools")  
    * Abdominal (midsection) discomfort, bloating, frequent gas pains 
Systemic Colo-rectal Cancer Symptoms: 
    * Unintentional weight loss 
    * Loss of appetite 
    * Unexplained fatigue (extreme tiredness) 
    * Nausea or vomiting 
    * Anemia (low red blood cell count or low iron in your red blood cells) 
    * Jaundice (yellow color to the skin and whites of the eye).  
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      DIAGNOSIS (6) 
• Barium enema X-ray 
• Colonoscopy 
• Ultrasonography 
• CT scan 
• Chest X-ray 
• Biopsy 
 I.1.11 TREATMENT (7) 
• Chemotherapy 
• Biological therapy  
• Radiation therapy  
• Laser treatment 
• Photodynamic therapy 
• Stem cell transplant 
I.2.1 Pim1 
The human pim-1 (proviral integration site for moleny murine leukaemia virus or 
MULV) oncogene is localized on chromosome 6p21.2, a fragile site M) involved in 
certain leukemias (8). Its cDNA contains an open reading frame of 313 codons with 
94% homology to the mouse counterpart. The RNA transcript is 2.9 kilo bases (kb) 
long (9). The pim1 protein is a serine/threonine kinase(10,11). Two ubiquitously 
expressed have been isoforms of human pim1 protein (35&34 kda ) have been  
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identified (12). In vitro human pim1 autophosphorylates and exhibits 
phosphotransferase activity towards various exogenous substrates (13). The crystals 
structure of pim1 reveal that it is a constitutively active kinase: phosphorylation of 
pim1 is not necessary for it kinase activity regulation but contributes to its stability 
(14)
. Immunoperoxidase staining using monoclonal antibodies have a shown that pim1 
protein is predominantly located in the cytoplasm, although nuclear or nucleo-
cytoplasmic patterns of localization have been described (15). 
I.2.2 Crystal Strucuture of Proto Oncogen Kinase Pim1 
Pim 1 is aproto-oncogene originally identified as a preferential proviral integration 
site in moloney murine leukemia virus induced T-cell lymphomas (16). Pim1 is the first 
described member of a uniquefamily of serine/ \threonine kinase with significant 
sequence homology to pim1 (17,18) several substrates of pim1 phosphorylation have 
been identified, including c-myb(19), BAD (20,21), SCOS (22), cdc25-A (23), HP1 
(24)
,PAP-1 (25). Pim1 contains an insertion in the hinge region and a proline residue at a 
key position (123) critical for ATP binding othe kinases have anon-proline residue at 
this position where the backbone NH of the residue makes a conserved hydrogen 
bond to ATP. It was confirmed by x-ray crystallography 
       Pim1 is often expressed in both normal and transformed cells to different degrees. 
It is expreesed in many cell lines derived from human lymphoid and myeloid 
malignancies, as well as in several human solid tumor cells. In humans the pim-1 
oncogene is expressed in lymphoid and haematopoitic malignancies, squamous cell 
carcinomas of the head and neck region , gastric carcinomas and colorectal 
carcinomas. 
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Pim1 is astrees reponse kinase which is regulated by cytokines (26-28) growth factors 
(29)
 hormones (30) by condition like ischemia (31) and cellular hypoxia (32)  as well as by 
infective agent such as the Epstein-Barr virus (33) and helicobacter pylorus(34). 
I.2.3 Molecular Function of Pim1 
Pim1 has been implicated in signal tranductional and transcriptional regulation, as 
well as cell cycle regulation and survival. These biological functions have been well 
and extensively reviwed elsewhere and are not within the scope of this review (35,36) 
here we provide a very general if necessary when addressing the expression of pim1 
in individual tissue types. 
The effect of pim1 in signal transduction is medicated by several players,adapter 
protein socl and soc3 are involved in negative regulation of cytokine induced JAK-
STAT signaling (37) the nuclear adapter protein p100(a pim1 binding partner ) is an 
activation factor of transcription factor c.myb (38). In addition, the NFATc protein is 
involved in relaying signals from t-cell receptor (39) 
Furthermore several pim1 substances have been identified, adding to the evidence that 
pim1 can regulate nuclear transcription. Induced HP1 (hetro chromatin- associated 
protein 1) and PAP1 (PIM1 associated protein) function in transcriptional repression 
by the silencing of chromatin and regulation of mRNA spilicing, respectively (40.41). 
I.2.4 Human Pim1 and malignancy: 
Human pim1 has multiple role in tumorigenesis. It promotes early transformation, cell 
proliferation (42), and cell survival (43,44). In addition it may have a role in angiogenesis 
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and vasculogenesis as a downstream effector of the VEGFA/F1K1 pathway (45). Pim1 
expression is correlated with tumor aggressiveness (46,47) and is a marker of poor 
prognosis (48) pim1 expression can be predictive of tumor outcome following 
chemotherapy (49) and surgery (50) and has been correlated with the enhanced 
metastatic potential of the role of pim1 in specific tumor types. 
• B-cell non-Hodgkin lymphomas  
• Leukemia  
• Prostate cancer 
• Squamous cell carcinoma  
• Gastrointestinal tumours  
• Pancreas cancer 
I.3 COMPUTATIONAL CHEMISTRY 
          Computational chemistry (51) is a branch of chemistry that uses principles 
of computer science to assist in solving chemical problems. It uses the results 
of theoretical chemistry, incorporated into efficient computer programs, to calculate 
the structures and properties of molecules and solids (52). Its necessity arises from the 
well-known fact that apart from relatively recent results concerning the hydrogen 
molecular ion, the quantum n-body problem cannot be solved analytically, much less 
in closed form. While its results normally complement the information obtained by 
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chemical experiments, it can in some cases predict hitherto unobserved chemical 
phenomena. It is widely used in the design of new drugs and materials. 
Calculate the following properties  (53) 
• structure (i.e. the expected positions of the constituent atoms), 
• absolute and relative (interaction) energies, 
• electronic charge distributions, 
•  dipoles and higher multipole moments,  
• vibrational frequencies,  
• reactivity or other spectroscopic quantities,  
•  cross sections for collision with other particles. 
The methods employed cover both static and dynamic situations. In all cases the 
computer time and other resources (such as memory and disk space) increase rapidly 
with the size of the system being studied. That system can be a single molecule, a 
group of molecules, or a solid. Computational chemistry methods range from highly 
accurate to very approximate; highly accurate methods are typically feasible only for 
small systems. Ab initio methods (54) are based entirely on theory from first principles. 
Other (typically less accurate) methods are called empirical or semi-empirical because 
they employ experimental results, often from acceptable models of atoms or related 
molecules, to approximate some elements of the underlying theory. 
Both ab initio and semi-empirical approaches involve approximations. These range 
from simplified forms of the first-principles equations that are easier or faster to solve, 
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to approximations limiting the size of the system (for example, periodic boundary 
conditions), to fundamental approximations to the underlying equations that are 
required to achieve any solution to them at all5. For example, most ab 
initio calculations make the Born–Oppenheimer approximation, which greatly 
simplifies the underlying Schrödinger equation by freezing the nuclei in place during 
the calculation. In principle, ab initio methods eventually converge to the exact 
solution of the underlying equations as the number of approximations is reduced. In 
practice, however, it is impossible to eliminate all approximations, and residual error 
inevitably remains. The goal of computational chemistry is to minimize this residual 
error while keeping the calculations tractable. 
In some cases, the details of electronic structure are less important than the long-
time phase space behavior of molecules. This is the case in conformational studies of 
proteins and protein-ligand binding thermodynamics. Classical approximations to the 
potential energy surface are employed, as they are computationally less intensive than 
electronic calculations, to enable longer simulations of molecular dynamics. 
Furthermore, cheminformatics uses even more empirical (and computationally 
cheaper) methods like machine learning based on physicochemical properties. One 
typical problem in cheminformatics is to predict the binding affinity of drug 
molecules to a given target (55). 
I.4.1 DRUG DESIGN 
Drug design, sometimes referred to as rational drug design or more simply rational 
design, is the inventive process of finding new medications based on the knowledge 
of a biological target (56). In the most basic sense, drug design involves the design of 
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small molecules that are complementary in shape and charge to the biomolecular 
target with which they interact and therefore will bind to it. Drug design frequently 
but not necessarily relies on computer modeling techniques.(57) This type of modeling 
is often referred to as computer-aided drug design. Finally, drug design that relies on 
the knowledge of the three-dimensional structure of the biomolecular target is known 
as structure-based drug design. 
The phrase "drug design" is to some extent a misnomer. What is really meant by drug 
design is ligand design (i.e., design of a small molecule that will bind tightly to its 
target).(58) Although modeling techniques for prediction of binding affinity are 
reasonably successful, there are many other properties, such 
as bioavailability, metabolic half-life, lack of side effects, etc., that first must be 
optimized before a ligand can become a safe and efficacious drug. These other 
characteristics are often difficult to optimize using rational drug design techniques. 
                               Typically a drug target is a key molecule involved in a 
particular metabolic or signaling pathway that is specific to a disease condition 
or pathology or to the infectivity or survival of a microbial pathogen. Some 
approaches attempt to inhibit the functioning of the pathway in the diseased state by 
causing a key molecule to stop functioning.  Another approach may be to enhance the 
normal pathway by promoting specific molecules in the normal pathways that may 
have been affected in the diseased state. 
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I.4.2 TYPE OF DRUG DESIGN 
  
Fig.I.3 Type of drug design                                                                                    
There are Two major types of drug design. The first is referred to as ligand-based 
drug design and the second, structure-based drug design. 
Ligand-based Drug design 
Ligand-based drug design (or indirect drug design) relies on knowledge of other 
molecules that bind to the biological target of interest. These other molecules may be 
used to derive a pharmacophore model that defines the minimum necessary structural 
characteristics a molecule must possess in order to bind to the target.(59) In other 
words, a model of the biological target may be built based on the knowledge of what 
binds to it, and this model in turn may be used to design new molecular entities that 
interact with the target.  
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Alternatively, a quantitative structure-activity relationship (QSAR), in which a 
correlation between calculated properties of molecules and their experimentally 
determined biological activity, may be derived. These QSAR relationships in turn 
may be used to predict the activity of new analogs. 
Structure-based Drug Design 
Structure-based drug design (or direct drug design) relies on knowledge of the three 
dimensional structure of the biological target obtained through methods such as x-ray 
crystallography or NMR spectroscopy.(60) If an experimental structure of a target is 
not available, it may be possible to create a homology model of the target based on 
the experimental structure of a related protein. Using the structure of the biological 
target, candidate drugs that are predicted to bind with high affinity and selectivity to 
the target may be designed using interactive graphics and the intuition of a medicinal 
chemist. Alternatively various automated computational procedures may be used to 
suggest new drug candidates. 
As experimental methods such as X-ray crystallography and NMR develop, the 
amount of information concerning 3D structures of biomolecular targets has increased 
dramatically. In parallel, information about the structural dynamics and electronic 
properties about ligands has also increased. This has encouraged the rapid 
development of the structure-based drug design.  
Active site identification 
Active site identification is the first step in this program. It analyzes the protein to find 
the binding pocket, derives key interaction sites within the binding pocket,  
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and then prepares the necessary data for Ligand fragment link. The basic inputs for 
this step are the 3D structure of the protein and a pre-docked ligand in PDB format, as 
well as their atomic properties. Both ligand and protein atoms need to be classified 
and their atomic properties should be defined, basically, into four atomic 
types:hydrophobic atom: All carbons in hydrocarbon chains or in aromatic groups. 
 H-bond donor: Oxygen and nitrogen atoms bonded to hydrogen atom(s). 
 H-bond acceptor: Oxygen and sp2 or sp hybridized nitrogen atoms with lone 
electron pair(s). 
 Polar atom: Oxygen and nitrogen atoms that are neither H-bond donor nor H-
bond acceptor, sulfur, phosphorus, halogen, metal, and carbon atoms bonded to 
hetero-atom(s). 
The space inside the ligand binding region would be studied with virtual probe atoms 
of the four types above so the chemical environment of all spots in the ligand binding 
region can be known. Hence we are clear what kind of chemical fragments can be put 
into their corresponding spots in the ligand binding region of the receptor. When we 
want to plant “seeds” into different regions defined by the previous section, we need a 
fragments database to choose fragments from. The term “fragment” is used here to 
describe the building blocks used in the construction process. The rationale of this 
algorithm lies in the fact that organic structures can be decomposed into basic 
chemical fragments. Although the diversity of organic structures is infinite, the 
number of basic fragments is rather limited. Before the first fragment, 
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 i.e. the seed, is put into the binding pocket, and other fragments can be added one by 
one, it is useful to identify potential problems. First, the possibility for the fragment 
combinations is huge. 
 
 
Fig.I.4 Flow chart of drug design 
A small perturbation of the previous fragment conformation would cause great 
difference in the following construction process. At the same time, in order to find the 
lowest binding energy on the Potential energy surface (PES) between planted 
fragments and receptor pocket, the scoring function calculation would be done for 
every step of conformation change of the fragments derived from every type of 
possible fragments combination. Since this requires a large amount of computation, 
one may think using other possible strategies to let the program works more 
efficiently. When a ligand is inserted into the pocket site of a receptor,  
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conformation favor for these groups on the ligand that can bind tightly with receptor 
should be taken priority. Therefore it allows us to put several seeds at the same time 
into the regions that have significant interactions with the seeds and adjust their 
favorite conformation first, and then connect those seeds into a continuous ligand in a 
manner that make the rest part of the ligand having the lowest energy. The 
conformations of the pre-placed seeds ensuring the binding affinity decide the manner 
that ligand would be grown. This strategy reduces calculation burden for the fragment 
construction efficiently. On the other hand, it reduces the possibility of the 
combination of fragments, which reduces the number of possible ligands that can be 
derived from the program. These two strategies above are well used in most structure-
based drug design programs. They are described as “Grow” and “Link”. The two 
strategies are always combined in order to make the construction result more 
reliable.(61)  
I.4.3 Scoring method 
Scoring functions for docking 
Structure-based drug design attempts to use the structure of proteins as a basis for 
designing new ligands by applying accepted principles of molecular recognition. The 
basic assumption underlying structure-based drug design is that a good ligand 
molecule should bind tightly to its target. Thus, one of the most important principles 
for designing or obtaining potential new ligands is to predict the binding affinity of a 
certain ligand to its target and use it as a criterion for selection. 
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One early method was developed by Böhm(62) to develop a general-purposed 
empirical scoring function in order to describe the binding energy. The following 
“Master Equation” was derived: 
 
where: 
 desolvation – enthalpic penalty for removing the ligand from solvent 
 motion – entropic penalty for reducing the degrees of freedom when a    ligand 
binds to its receptor 
 configuration – conformational strain energy required to put the ligand in     its 
"active" conformation 
 interaction – enthalpic gain for "resolvating" the ligand with its receptor 
I.4.4 Rational drug design 
In contrast to traditional methods of drug discovery, which rely on trial-and-
error testing of chemical substances on cultured cells oranimals, and matching the 
apparent effects to treatments, rational drug design begins with a hypothesis that 
modulation of a specific biological target may have therapeutic value. In order for a 
biomolecule to be selected as a drug target, two essential pieces of information are 
required. The first is evidence that modulation of the target will have therapeutic 
value. This knowledge may come from, for example, disease linkage studies that 
show an association between mutations in the biological target and certain disease 
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states. The second is that the target is "drugable". This means that it is capable of 
binding to a small molecule and that its activity can be modulated by the small 
molecule. 
Once a suitable target has been identified, the target is normally cloned and expressed. 
The expressed target is then used to establish a screening assay. In addition, the three-
dimensional structure of the target may be determined. 
The search for small molecules that bind to the target is begun by screening libraries 
of potential drug compounds. This may be done by using the screening assay (a "wet 
screen"). In addition, if the structure of the target is available, a virtual screen may be 
performed of candidate drugs. Ideally the candidate drug compounds should be "drug-
like", that is they should possess properties that are predicted to lead to oral 
bioavailability, adequate chemical and metabolic stability, and minimal toxic effects. 
Several methods are available to estimate druglikeness such Lipinski's Rule of 
Five and a range of scoring methods such as Lipophilic efficiency. Several methods 
for predicting drug metabolism have been proposed in the scientific literature, and a 
recent example is SPORCalc.(63) Due to the complexity of the drug design process, 
two terms of interest are still serendipity and bounded rationality. Those challenges 
are caused by the large chemical space describing potential new drugs without side-
effects. 
I.4.5 COMPUTER AIDED DRUG DESIGN 
Computer-aided drug design uses computational chemistry to discover, enhance, or 
study drugs and related biologically active molecules.  
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The most fundamental goal is to predict whether a given molecule will bind to a target 
and if so how strongly. Molecular mechanics or molecular dynamics are most often 
used to predict the conformation of the small molecule and to model conformational 
changes in the biological target that may occur when the small molecule binds to 
it. Semi-empirical, ab initio quantum chemistry methods, or density functional 
theory are often used to provide optimized parameters for the molecular mechanics 
calculations and also provide an estimate of the electronic properties (electrostatic 
potential, polarizability, etc.) of the drug candidate that will influence binding affinity. 
Molecular mechanics methods may also be used to provide semi-quantitative 
prediction of the binding affinity. Also, knowledge-basedscoring function may be 
used to provide binding affinity estimates. These methods use linear 
regression, machine learning, neural netsor other statistical techniques to derive 
predictive binding affinity equations by fitting experimental affinities to 
computationally derived interaction energies between the small molecule and the 
target.(64,65)  
Ideally the computational method should be able to predict affinity before a 
compound is synthesized and hence in theory only one compound needs to be 
synthesized. The reality however is that present computational methods are imperfect 
and provide at best only qualitatively accurate estimates of affinity. Therefore in 
practice it still takes several iterations of design, synthesis, and testing before an 
optimal molecule is discovered. On the other hand, computational methods have 
accelerated discovery by reducing the number of iterations required and in addition 
have often provided more novel small molecule structures. 
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Drug design with the help of computers may be used at any of the following stages of 
drug discovery: 
1. hit identification using virtual screening (structure- or ligand-based design) 
2. hit-to-lead optimization of affinity and selectivity (structure-based 
design, QSAR, etc.) 
3. lead optimization optimization of other pharmaceutical properties while 
maintaining affinity 
 
 
  Fig.I.5  Flowchart of a Usual Clustering Analysis for Structure-Based Drug Design 
In order to overcome the insufficient prediction of binding affinity calculated by 
recent scoring functions, the protein-ligand interaction and compound 3D structure 
information are used to analysis. For structure-based drug design, several post-
screening analysis focusing on protein-ligand interaction has been developed for 
improving enrichment and effectively mining potential candidates: 
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 Consensus scoring(66,67)  
 Selecting candidates by voting of multiple scoring functions 
 May lose the relationship between protein-ligand structural      
information and scoring criterion 
 Geometric analysis 
 Comparing protein-ligand interactions by visually inspecting 
individual structures 
 Becoming intractable when the number of complexes to be analyzed 
increasing 
 Cluster analysis(68,69)  
 Represent and cluster candidates according to protein-ligand 3D 
information 
 Needs meaningful representation of protein-ligand interactions. 
A particular example of rational drug design involves the use of three-dimensional 
information about biomolecules obtained from such techniques as X-ray 
crystallography and NMR spectroscopy. Computer-aided drug design in particular 
becomes much more tractable when there's a high-resolution structure of a target 
protein bound to a potent ligand. This approach to drug discovery is sometimes 
referred to as structure-based drug design. The first unequivocal example of the 
application of structure-based drug design leading to an approved drug is the carbonic 
anhydrase inhibitor dorzolamide, which was approved in 1995.(70,71)    
 
 
  
 
 
 
 
 
 
 
 
Review of 
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                       II REVIEW OF LITERATURE  
• The review of literature is limited to last 10 years because the establishment of 
pim kinase had been from the past 10 years.  
• Focus of the literature review revolves around receptor site identification, 
Pharmacophore modeling, Docking study significance etc  
II.1TARGET SITE IDENTIFICATION 
• Tarm moroy., et al.,(72) (1993) reported the Expression of a pim-1 transgene 
accelerate lymphoproliferation and inhibits apoptosis in lpr/lpr mice. 
Transgenic mice expressing the Pim-1 kinase are predisposed to develop T-cell 
lymphomas with a long latency period of about 7-9 months. However, the exact 
functional basis of the oncogenic activity of Pim-1 remains obscure. 
• D wingett., et al.,(73) (1996) reported the pim-1 proto-oncogene expression in 
antiCD3 mediated T cell activation is associated with protein kinase activation 
and is independent of Raf-1. We have studied pim-1 proto-oncogene expression 
in human T cell responses to Ag receptor-generated signals. The pim-1 gene 
encodes a serine/threonine protein kinase that is expressed primarily in cells of 
hematopoietic lineage and is implicated in the intracellular signaling processes 
accompanying lymphocyte activation. We show here that pim-1 mRNA 
expression is rapidly induced after receptor cross-linking with anti-CD3 Abs. 
• Chrystal K.palaty., et al.,(74) (1997) reported Identification of the 
Autophosphorylation sites of the Xenopus laeuis pim-1 proto-oncogene-
encoded protein kinase . Pim-1 is an oncogene-encoded serine/threonine kinase 
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expressed primarily in cells of the hematopoietic and germ line lineages. 
Previously identified only in mammals, pim-1cDNA was cloned and sequenced 
from the African clawed frogXenopus laevis. 
• Tony J pircher., et al.,(75) (2000) repoted pim-1 kinase protect hemopoitic 
FDC cellfrom genotoxin-induced death.    
• Marcos. M., et al., (76) (2001) reported cell cycle as a critical decision in the 
treatment of cancer as to cycle or not. 
• James Thompson., et al.,(77) (2003) reported the Attenuation of Androgen 
Recptor-Dependent transcription by the serine/theronine kinase pim-1. 
oncogenic serine/threonine kinase, Pim-1, was reported to be overexpressed in 
prostate cancer.To elucidate whether Pim-1 is capable of modulating androgen 
signaling, we studied the effects of Pim-1 on androgen receptor (AR)-
dependent transcription. 
• Hitoshi.O., et al.,(78) (2004) showed the pathways of apoptotic and non 
apoptotic death in tumor cells. 
• Kju-Taekim., et al.,(79) (2005) reported pim-1 is up-regulated by constitutely 
activated FLT3 and play a role in FLT3-mediated cell survival. Pim-1 was 
found to be one of the most significantly down-regulated genes upon FLT3 
inhibition. Pim-1 is a proto-oncogene and is known to be up-regulated by signal 
transducer and activator of transcription 5 (STAT5), which itself is a 
downstream target of FLT3 signaling. 
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• Abhinau kumar., et al.,(80) (2005) showed the crystal structure of proto-
oncogene kinase pim1:A Target of Aberrent somatic hyper mutation in diffuse 
large cell lymphoma. While pim1 has been shown to be involved in several 
hematopoietic cancers, it was also recently identified as a target of aberrant 
somatic hypermutation in diffuse large cell lymphoma (DLCL), the most 
common form of non-Hodgkin’s lymphoma. 
• Jacobs MD., et al.,(81) (2005) reported the pim-1 ligand –bound structure 
reveal the mechanism of serine/theronine kinase inhibition by LY294002. Pim-
1 kinase 
• was originally identified in Maloney murine leukemia virusinduced T-cell 
lymphomas and is associated with multiple cellular functions such as 
proliferation, survival, differentiation, apoptosis, and tumorigenesis 
• Charline peng., et al.,(82) (2007) reported the pim kinase substrate 
identification and specificity. The Pim family of Ser/Thr kinases has been 
implicated in the process of lymphomagenesis and cell survival. Known 
substrates of Pim kinases are few and poorly characterized. In this study we set 
out to identify novel Pim-2 substrates using the Kinase Substrate Tracking and 
Elucidation (KESTREL) approach. 
• Nilesh shah., et al.,(83) (2008) reported the potential role for the pim1 kinase in 
human cancer-A molecular and therapeutic appraisal. The Pim1 kinase is a true 
oncogene implicated in early transformation and tumour progression in 
haematopoietic malignancies and prostate carcinomas 
• Rebbeka grundler., et al.,(84) (2009) reported the Dissection of Pim 
serine_threonine kinases in FLT3-ITD–induced leukemogenesis reveals Pim1 
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as regulator of CXCL12–CXCR4-mediated homing and migration. FLT3-ITD–
mediated leukemogenesis is associated with increased expression of oncogenic 
Pim serine/threonine kinases. 
• Xieu Feng Hu., et al.,(85) (2009) reported the  Pim-1–specific mAb suppresses 
human and mouse tumor growth by decreasing Pim-1 levels, reducing Akt 
phosphorylation, and activating apoptosis. Overexpression of Pim-1 plays a 
critical role in progression of prostatic and hematopoietic malignancies. Here 
we describe the generation of a mAb specific for GST–Pim-1, which reacted 
strongly with most human and mouse cancer tissues and cell lines of prostate, 
breast, and colonorigin but only weakly (if at all) with normal tissues  
• Jongchain kim., et al.,(86) (2010) reported the pim1 promotes human prostate 
cancer cell tumorigenicity and C-myc transcriptional activity. We 
overexpressed Pim1 in three human prostate cell lines representing different 
disease stages including benign (RWPE1), androgen-dependent cancer 
(LNCaP) and androgen-independent cancer (DU145). 
• Sengjie Guo., et al.,(87) (2010) reported the Overexpression of pim-1 in 
Bladder cancer. Expression and localization of Pim-1 in human normal and 
malignant bladder specimens were examined by Immunohistochemistry and 
Pim-1 staining score was compared with several clinicopathologic parameters. 
• Laurent Brault., et al.,(88) (2010) showed the Pim serine_threonine kinases in 
the pathogenesis and therapy of hematologic malignancies and solid cancers. 
Whereas elevated levels of Pim1 and Pim2 were mostly found in hematologic 
malignancies and prostate cancer, increased PIM3 expression was observed in 
different solid tumors 
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• Methvin Isaac., et al.,(89) (2011) reported the oncogenic pim kinase family 
regulation drug resistance through multiple mechanisms. Resistance to 
chemotherapeutic drugs is a significant clinical problem for the treatment of 
cancer patients and has been linked to the activation of survival pathways and 
expression of multidrug efflux transporters. 
• Amir T.Faith., et al.,(90) (2012) showed a potential therapeutic target for 
FLT3-ITD AML: pim1 kinase. Pim1, a serine/threonine kinase, is up-regulated 
in FLT3-ITD AML and may be involved in FLT3-mediated leukemogenesis. 
We employed a Pim1 inhibitor. 
• Yasid Alvarado., et al.,(91) (2012) reported the pim kinases in hematological 
cancer. The PIM genes represent a family of protooncogenes that encode three 
different serine/threonine protein kinases (Pim1, Pim2 and Pim3) with essential 
roles in the regulation of signal transduction cascades, which promote cell 
survival proliferation and drug resistance. 
II.2 PHARMACOPHORE MODELING 
• Marc D Jacobs., et al.,(92) (2005) reported the pim-1 ligand-bound structure 
reveal the mechanism of serine/theronine kinase inhibition by LY294002. The 
crystal structures of Pim-1 complexed with staurosporine and adenosine were 
determined. Although a typical two-domain serine/threonine protein kinase fold 
is observed, the interdomain hinge region is unusual in both sequence and 
conformation; a two-residue insertion causes the hinge to bulge away from the 
ATP-binding pocket, and a proline residue in the hinge removes a conserved 
main chain hydrogen bond donor 
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• Sheldon holder., et al.,(93)  (2007) reported the comparative molecular field 
analysis of flavanoid inhibitors of the pim-1 kinase. Comparative molecular 
field analysis (CoMFA) is a 3-D QSAR technique that has been widely used, 
with notable success, to correlate biological activity with the steric and 
electrostatic properties of ligands. 
• Sheldon holder., et al.,(94) (2007) reported the Characterization of a potent and 
selective small-molecule inhibitor of the Pim1 kinase. We have used 
experimental approaches to identify a selective, cell-permeable, small-molecule 
inhibitor of the pim-1 kinase to foster basic and translational studies of the 
enzyme. 
• Vanda pogacic., et al.,(95) (2007) reported the structural analysis identifies 
Imidazo [1,2-b] pyridazine as pim kinase inhibitors with invitro antileukemic 
activity. Using protein stability shift assays, we identified a family of 
imidazo[1,2-b]pyridazines to specifically interact with and inhibit Pim kinases 
with low nanomolar potency. 
• Albert C.pierce., et al.,(96) (2008) showed the Docking Study Yields Four 
Novel Inhibitors of the Protooncogene Pim-1 Kinase. 
• Kevin Qian., et al.,(97) (2009)  showed the Hit to Lead Account of the 
Discovery of a New Class of Inhibitors of Pim Kinases and Crystallographic 
Studies Revealing an Unusual Kinase Binding Mode. 
• Rufane Akuae-Gedu., et al.,(98) (2009) reported the Synthesis, Kinase 
Inhibitory Potencies, and in Vitro Antiproliferative Evaluation of New Pim 
Kinase Inhibitors . 
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• Stefania olla., et al.,(99) (2009) reported the Indolyl-pyrrolone as a new scaffold 
for pim-1 inhibitors. In this work, we applied a virtual screening protocol 
aimed at identifying small molecules able to inhibit Pim1 activity. 
• Silmae Dovdou., et al.,(100) (2010) reported the Inhibitors of Pim-1 Kinase_ A 
Computational Analysis of the Binding Free Energies of a Range of Imidazo 
[1,2-b] Pyridazines. 
• Miviam Lopez-Ramos., et al.,(101) (2010) showed the New potent dual 
inhibitors of CK2 and Pim kinases: discovery and structural insights. Protein 
kinase casein kinase 2 (CK2) is a serine/threonine kinase with evidence of 
implication in growth dysregulation and apoptosis resistance, making it a 
relevant target for cancer therapy. 
• Xiangy., et al.,(102) (2011) showed the the discovery of novel bezofuran 2-b 
carboxylic acid as potent pim-1 inhibitors. 
• Nishighchi GA., et al.,(103) (2011) reported the Discovery of novel 3,5 
disubstituted indole derivative as potent inhibitors of pim-1,pim-2 and pim-3 
protein kinases. 
• JI-Xia Ren., et al.,(104) (2011) reported the Discovery of Novel Pim-1 Kinase 
Inhibitors by a Hierarchical Multistage Virtual Screening Approach Based on 
SVM Model, Pharmacophore, and Molecular Docking. 
• Carmen Blanco-Aparicio., et al.,(105) (2012) reported the  pim-1 kinase 
inhibitors ETP-45299 suppress cellular proliferation and synersizes with P13K 
inhibition. Hence pharmacologic inhibitors of Pim 1 are of therapeutic interest 
for cancer. ETP-45299 is a potent and selective inhibitor of Pim 1 that inhibits 
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the phosphorylation of Bad and 4EBP1 in cells and suppresses the proliferation 
of several non-solidand solid human tumor cell line 
• Keiko Tsuganezawa et al(106) 2012 showed the a novel pim-1 kinase inhibitor 
targeting residue that bond the substrate peptide. Using the method, among 
approximately 700 candidate compounds selected by virtual screening, we 
identified a novel Pim-1 kinase inhibitor targeting its peptide binding residues 
• Kilian Haber., et al.,(107) (2012) reported the 7,8-Dichloro-1-oxo-ß-carbolines 
as a Versatile Scaffold for the Development of Potent and Selective Kinase 
Inhibitors with Unusual Binding Modes. The innate promiscuity of kinase 
inhibitors largely results from ATP-mimetic binding to the kinase hinge region. 
• Pastor J., et al.,(108) (2012)  showed the Hit to lead evaluation of 1,2,3-
triazolo[4,5-b] pyridine as pim kinase inhibitors. Pim kinases have become 
targets of interest due to their association with biochemical mechanisms 
affecting survival, proliferation and cytokine production. 1,2,3-Triazolo[4,5-
b]pyridines were identified as PIM inhibitors applying a scaffold hopping 
approach 
II.3 DOCKING STUDY SIGNIFICANCE 
• Andrew L H.,(109) (2002) carried and assessment of molecular targets that 
represent an opportunity for therapeutic intervention. 
• Paul, D.L.,(110)(2002) showed an overview on the significance of receptor based 
virtual screenings. 
• Jack K., (111) (2003) showed the basis of the hydrophobic effect as one of the 
important for docking. 
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• Gregory, L.W., et al.,(112) (2005) reported the evaluation of 10 docking 
programs and 37 scoring function as an assessment of docking programs and 
scoring functions. 
• Ajay N. J., (113) (2006) showed the importance and varies aspect of scoring 
functions for protein- ligand docking. 
• Gerhard,K., (114)(2006) showed the review and process description involved in 
virtual ligand screening. 
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                         III AIM AND OBJECTIVES 
The course of the study and research has been to identify new molecule for 
anticancer  capable to inhibit pim 1 hence the following processes were carried 
out. 
• Identification of Common Pharmacophore for Pim1. 
• Preparation of database of ligands. 
• Scaffold identification by docking.  
• Investigation of ADME parameters of selected molecules. 
• Synthesis of molecules related to scaffhold. 
• Characterization of synthesized molecules by TLC, IR spectroscopy, Nuclear 
Magnetic Resonance spectroscopy and mass spectroscopy. 
• Acute toxicity study in albino mice 
• In vitro Anticancer Investigation of synthesized molecules against HCT cell 
lines  
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                                     IV.2 DRUG DESIGN                
               IV. 2a PHARMACOPHORE MODELING 
IV.2a.i Pharmacophore 
Pharmacophore means “a molecular framework that carries (phoros) the essential features 
responsible for a drug (pharmacon) biological activity”. A pharmacophore is defined as “a 
set of structural features in a molecule that is recognized at a receptor site and is responsible 
for that molecule’s biological activity”. 
Pharmacophore features 
The typical chemical features are as follows:  
• Hydrogen bond acceptor 
• Hydrogen bond  donor 
• Hydrophobic 
• Hydrophobic aliphatic 
• Hydrophobic aromatic 
• Positive ionizable 
• Negative ionizable 
• Ring aromatic. 
All the above pharmacophore features need to match different chemical groups with similar 
properties. 
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Pharmacophore Studies: (Catalyst) 46 
 CATALYST (Tm), an Accelrys developed software is used for pharmacophore generation. 
Catalyst treats molecular structures as templates comprising of chemical functions 
positioned in space that will bind efficiently with complementary functions on the 
respective binding proteins. Catalyst generates pharmacophore hypotheses in terms of the 
3D arrangement of chemical functional group elucidating the activity variations of the 
compounds. The total energy cost of the each generated hypothesis can be calculated from 
the difference between the observed activity value and the activity value estimated by the 
hypothesis based on the pharmacophore features. 
Cerius 2 47 
 Cerius2 is a product of accelrys. Cerius2 has a variety of force fields available. The default 
force field is UFF, which stands for universal force field.Cerius2 offers abilities for 
modeling materials structure properties, and processes with appliances in catalysis, 
crystallization and polymer science. Cerius2 is a suite of molecular modeling and 
simulation package for smaller molecules. 
IV.2a.ii Chemical Feature based based models from Catalyst4.11 
Catalyst is a program package from accelyrs. The program provided a modeling 
environment and consists of several modules, which can be bought independently. Below is 
a description of the module important for database search and hypothesis generation. In 
Catalyst, 3D-pharmacophore model and queries for searching 3D database are called 
hypothesis. 
HipHop 
Generate a set of common feature pharmacophore model from set of compounds known to 
be active (No activity data) at a target 
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HypoGen  
Develop SAR hypothesis model from a set of molecules for which activity values (IC50 or 
Ki) on a given biological target are known. 
HypoRefine 
Permits consideration of exclusion volume in Pharmacophore-based 3D QSAR 
optimization. The result is better model predictivity activity is determined by considerations 
of molecular shape. 
Exclusion volume  
 An exclusion volume can be added to a hypothesis (or to a template molecules) to specify 
one or more spherical spaces that must not contain any atoms or bonds. An exclusion 
volume can represent a region in space that might impinge sterically on a receptor. An 
exclusion volume can be interpreted as a geometrical constraint, and this is how it is treated 
in catalyst. 
Compare/Fit 
Provide the ability to fit compounds and hypotheses, and determine their degree of 
similarity, both geometrically and functionally. In a database search, COMPARE fits the 
original hypothesis onto the hit molecules obtained from the search and a score are 
calculated according to the geometrical fit. 
Cost Parameters 
1. Fixed cost represents the simplest possible hypothesis (initial) that fits the data perfectly. 
2. Null hypothesis 
It is the cost when each molecule estimated a mean activity. It acts like a hypothesis with 
no feature. 
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3. Error cost 
The bits needed to describe the error in the leads. It increases as the RMS difference 
between estimated and measured activities for training set molecules increases. 
4. Weight cost  
The bits required to describe the feature weights. 
5. Configuration cost 
The bits required to describe the types and relative position of the feature in the hypothesis. 
A fixed cost that depends on the  
• Main assumption made by HypoGen is that active molecules  
• Should map more features than an inactive molecules 
• Complexity of the hypothesis space being optimized 
IV.2a.iii PHARMACOPHORE STUDIES 
Pharmacophore elucidation is a molecular alignment problem, the aim being to 
superimpose a set of active ligands, all of which bind to the same protein of unknown 3D 
structure, so that the features they have in common become evident. 
 The model is a collection of chemical features distributed in 3D space that is intended to 
represent groups in molecules that participate in important binding interaction ions between 
drugs and their receptor. Estimated activity computed by comparing how well the chemical 
feature of a subject molecules overlap with the chemical features in the model (hypo). The 
ability of molecules to adjust their conformation in order to fit a receptor better is 
accommodated by considering molecules as collections of energetically reasonable 
conformation (confo model) during analysis. 
The step involved in the development of pharmacophore model: 
• Visual identification of common structural and chemical feature  
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• Measurements of 3D aspects of pharmacophore  
• Development of pharmacophore model 
• Validation of model 
• Refinement of model   
Data collection and development of database 
Pim1 inhibitors data have been collected with their biological activity data from various 
medicinal chemistry as well as life science journals and developed a unique database using 
MDL ISIS/Base. Our pim1 inhibitors database contains 91 compounds were selected based 
on diversity of both chemical structure and biological activity. 
Training set selection and conformational generation  
The most critical aspect of pharmacophore hypothesis generation is the selection of the 
training set. The 91 molecules were arranged in decreasing order of their activity. The most 
diverse 24 molecules were carefully selected as the training set.  
Highly active (+++ or < 1µM), moderatively active(++or 1-10µM)  and inactive(+ or 
>10µM) compound were added to training set to obtain critical information on 
pharmacophore requirements for pim1 inhibition. 
Before starting the pharmacophore generation process, conformation models for the 
molecules was developed by poling algorithm, which seeks to provide a broad coverage of 
conformational space using the best conformer generation method with a maximum 
conformational energy of 20kcal/mol above the lowest energy conformation found. The 
number of conformers generated for each compound was limited to a maximum number of 
250.this training set was then used to generate quantitative pharmacophore model. 
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Generate of HipHop (Qualitative) model 
HipHop hypothesis were produced by comparing a set of conformational model and a 
number of 3D configurations of chemical features shared among the training set molecules 
with diverse scaffolds. 
The automatic hypothesis generation with HipHop was done by the following procedure: 
• For each compound a best quality conformational model was generated with default 
parameters;max number =250 and energy range = 20 kcal/mol. 
• An automatic hypothesis generation was run . The hypothesis was allowed to 
contain the features: 0-5 “hydrophobic”, 0-5 “HB Acceptor feature” (default), 0-5 
“HB donor”, 0-5 “Positive ionisable”, and 0-5 “Ring aromatic “based on Lipinski 
rules. 
• All the parameters were set to default. Therefore the program will stop after 10 
hypothesis are generated. 
Generation of HypoGen(Quantitative)model 
The training set of 24 molecules defined earlier was used in HypoGen pharmacophore 
model, which could be used for quantitative estimation of activities while screening large 
databases. 
• The automatic hypothesis generation with hiphop was done by the following 
procedure: 
• Input structures were selected from the criteria that they should share the same 
binding mode, be structurally diverse, and the affinity data should cover several 
orders of magnitude.  
• For each compound a best quality conformational model was generated with default 
parameters;max number =250 and energy range = 20 kcal/mol. 
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• The compound were associated with an uncertainty of 3 
• An automatic hypothesis generation was run. The hypothesis was allowed to contain 
the features :0-5 “hydrophobic”, 0-5 “HB Acceptor feature” (default), 0-5 “HB 
donor”, 0-5 and 0-5 “Ring aromatic “. 
• All the parameters were set to default. Therefore the program will stop after 10 
hypotheses are generated. 
Generated quantitative Pharmacophore models are used to predict biological activities of 
novel compounds. The quality of hypogen model is described in term of cost analysis. 
Generate of Hyporefine hypotheses 
The automatic hypothesis generation with hyporefine was done by same procedure as 
hypogen but with excluded volume. 
Cost analysis during Pharmacophore Model 
During an automated hypothesis generation run, catalyst considers and discards many 
thousands of models. It distinguishes between alternatives by applying a cost analysis. Here 
the simplest model is used. Simplicity is defined using the minimum description length 
principle from information theory. Catalyst uses bits for language, so the program assigns 
costs to hypothesis in terms of the number of bits required to illustrate them fully. The 
overall cost of a hypothesis is determined by summing three cost factors, a weight cost, an 
error cost and a configuration cost. Error cost has the major effect in establishing 
hypothesis cost. The differences between these two costs are essential, the greater the 
differences the higher the possibility for finding useful models. 
If a returned hypothesis has a cost that differs from the null hypothesis by 40 – 60bits there 
is a high probability it has a 75-90% chance of demonstrating a true correlation in the data. 
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As the difference becomes less than 40 bits, the likelihood of the hypothesis demonstrating 
a true correlation in the data rapidly drops below 50 percent under these conditions it may 
be difficult to find a model that can be shown to be predictive. The output from the catalyst 
hypothesis generations job is the ten lowest cost hypotheses establish during the analysis 
that are different from each other. It is not often not possible to categorize between these by 
any simple statistical procedure particularly if the cost difference are small (<10bits). 
A visual evaluation procedure is used to select the best model comparing the regression 
graphs, obtained by correlating the train set data, Using the compare fit it was seen how the 
most active compounds map to the model. This is where chemical relevance established. To 
predict in a useful way, a model should be capable of explaining the difference in activity 
between training set members in a way that is chemically reasonable. The process is also 
dependent on how good the conformation coverage is for each training set. Often, a fit 
produced during the automatic generation phase can be improved using the best fit compare 
operation, compound whose activities. 
Generation of Pharmacophore Models 
Following the basic principle of training set selection, 24 compounds were exquisitely 
chosen with their shown in figure IV.1. Training and test set compounds taken from our in-
house database were imported into CATALYST™, and submitted for conformational 
analysis. 
Training set compound were used for generating pharmacophore model 
Pharmacophore model were developed using hypogen module implement in CATALYST 
and the top 10 scoring hypothesis were exported. Analyses of the best ranking 
pharmacophore model revealed that four chemical feature that are two H-bond acceptor, 
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one hydrophobic aliphatic and ring aromatic feature could effectively map all the chemical 
feature. The activity of each training set compound is estimated using regression 
parameters. The parameters are computed by the regression analysis using the relationship 
of geometric fit values versus the negative logarithm of activity. The grater the geometric 
fit, the greater the activity prediction of the compound. The fit function does not only check 
if the feature mapped or not; it also contains a distance term which measure the distance 
term which measure the distance that separates the feature on the molecules from the 
centroid of the hypothesis feature. Both terms are used to calculate the geometric fit value. 
The error value shows the ratio of estimated activity to experimental activity. A positive 
error values indicates that the estimated IC50 is higher than the experimental IC50 while a 
negative error value indicates that the estimated IC50 is lower than the experimental IC50.  
Pharmacophore Model validation and knowledge based screening 
The best pharmacophore hypothesis was used initially to screen 30 pim-1 inhibitors test set. 
The same model has also been used to select potent molecules from 1000 library molecules 
designed using scaffold hoping (knowledge based screening). 
Pharmacophore Model validation  
The main purpose of validating a qualitative model is to determine whether our model is 
able to identify active structures and forecast their actively accurately. The purpose of the 
pharmacophore hypothesis generation is not just to predict the activity of the training set 
compounds accurately but also to verify whether the pharmacophore model are capable of 
predicting the activity for any given compounds and classifying them correctly as active or 
inactive. 
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Fig. IV.1 Training set 24 molecules for pim-1 inhibitors. IC50 values of each molecule are 
given in parentheses 
In order to validate our Pharmacophore hypothesis, we have used a training set comprising 
of molecules which had experimental pim-1 inhibitory activity belonging to different 
activity ranges and the randomize the activity data associated with the training set 
compounds, and randomized training sets are used to generate pharmacophore  hypothesis 
using the same features and parameter as developed for the original hypothesis. If 
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randomized data set results in the generation of a Pharmacophore with similar or better cost 
values, RMSD, and correlation, then the original hypothesis is considered to have been 
generated by chance. 
The best Pharmacophore hypothesis was used initially to screen the pim-1 inhibitors. All 
queries were performed using the best flexible search database/SS method. The hyporefine 
was used to screen the known highly active, moderate active, low active inhibitors of the 
test set. 
The correlation between experimental and predicted value for the test set molecules against 
hypo-1 model along with training set molecules for pim-1 inhibitors. The features mapped 
by this pharmacophore are two hydrogen bond acceptor, Hydrogen bond donor and one 
hydrophobic. 
The high active compound is identified from the result of hyporefine process and the 
compound study on perfect fit for structure as a scaffold is performed. Adding then in 
appropriate position of scaffold identifies the respective attachment groups.The activity of 
catalyst compound is then populated by applying Lipinski rule identified the property of 
new catalyst compound. Underestimated nearly always give improved value when fitted 
under best fit compare. 
During automatic hypothesis generation, catalyst uses the fast fit compare algorithm to 
measure fits of molecule to a model. The best fit compare always starts with the fast fit and 
attempts to improve the fit by allowing the induced conformation to flex over a given 
energy range. In effect, more of the relevant conformation space is examined during this 
process. Look for model that explains the activity of most of the training set members in a 
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chemically reasonable way and estimated their activities to within a power of 10 of 
measured values. This critical step toward establish productiveness of the model, if the 
model successfully predicts the activities of these outsiders and does so while mapping the 
compounds in chemically reasonable ways, it is good candidate for use as a model to guide 
future synthesis. 
Knowledge based screening  
A total of 1000 molecules were generated based on the knowledge of binding interaction of 
ligand with the protein and also the common features necessary for the biological activity 
of molecules. These molecules were drawn using cerius software and were screened for 
their activities using the developed Pharmacophore models. For the final screening of the 
compounds, the hits were analyzed in the Pharmacophore model and the most active hits 
were identified. Best flexible search method in CATALYST was used for database 
searching to retrieve similar feature compounds.  
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                        IV.2.b DOCKING STUDY 
Docking procedures aim to identify correct posses of ligands in the binding pocket of 
the protein and to identify and to predict the affinity between the ligands and the 
protein, in other words docking describes a process by which molecules fit together in 
three dimensional space. 
Basic requirements for molecular docking approach require the following 
components. A target protein structure with or without a bound ligand ,the molecules 
of interest or a database containing existing or virtual compounds for docking posses 
and a computational framework that allows the implementation of the desired  
docking and scoring procedures for which the following steps are involved . 
• Selection and investigation of protein 
• Protein preparation 
• Receptor grid generation 
• Ligand database creation 
• Ligand preparation 
• Ligand receptor docking and predicting activity 
• Scaffhold identfication 
• Docking of molecules going to be synthesized 
IV.2.b.i SELECTION AND INVESTIGATION OF PROTEIN  
The protein selection is carried out from the  PDB (protein data bank).  Protein data 
bank is resource for studying biological macromolecules. It contains information 
about experimentally determined structures of proteins, nucleic acids and complex 
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assemblies.  Also providing a variety of tools and resources users can perform  simple 
and advanced searches based on annotations, relating to sequences, structures and 
function. 
The protein PDB file was selected for Pim1 and further evaluated by its Resolution 
value, R Free, R value and Ramachandran plot. 
IV.2.b.ii PROTEIN PREPARATION  
At first the protein which needs to be prepared is uploaded in the main menu by the 
option import PDB file and then the following steps are carried out Pim1 proteins.  
In this portion we amend the structures and perform the basic preparation tasks for the 
preparation of raw protein downloaded from the protein data bank which needs to be 
prepared for accurate results.  The task includes the following.  
• Align to options 
• Assign bond order option 
• Add hydrogen option 
• Crete zero order bond to metals option 
• Create disulfide bonds option 
• Convert selenomethionines to methionines option 
• Fill in missing side chains using prime option 
• Cap termini option 
• Fill in missing loops using prime option 
• Delete water beyond NA from het group’s option and text box. 
• Preprocess button 
                                                                                               DOCKING STUDY 
 
Department of Pharmaceutical Chemistry                                                                   Page 51 
 
The above steps are done in the”Maestro 9.1” protein preparation wizard. The 
workflow contains this tool which carries the steps necessary for preparation of 
protein. After processing all the above steps we will be able to say whether the protein 
is ready to be forwarded to the next step. 
IV.2.b.ii RECEPTOR GRID GENERATION  
Defining the Receptor (We need to define the part of the system in the workspace to 
be treated as a Receptor (Active site), PDB file of PIM1 (which were prepared earlier 
by protein preparation Wizard) were loaded on the workspace to generate their 
respective Grid files) 
Receptor Site Information 
The choice of receptor site can be done in 2 ways 
1) Centroid of workspace ligand    
2) Centroid of selected residues  
The process of receptor grid generation is done by using Glide® of Maestro 9.1 
molecular modeling suite. This software helps the identification of receptor grid 
according to our needs.  
The process is carried out after the particular protein been prepared in the protein 
preparation wizard and then the application tool  helps us to complete the grid 
generation. This gives an output file which  can be save it as Grid output file in zip 
format. 
 
                                                                                               DOCKING STUDY 
 
Department of Pharmaceutical Chemistry                                                                   Page 52 
 
The information about the receptor site of two receptors is: 
Pim1 (3R04) 
As per the literature of this particular pdb file, 3R04 gives information that 
hydrophobic interactions play a vital role in pim1 receptor binding. Hinge region 
residues P125 and surrounded by A65, R122, L44, L174. The preferable conserved H-
bonding interactions between water and E85, D186. The Hydrophobic interaction and 
H bonding needs to be investigated, so as to validate our affinity with receptor site. 
 
Fig IV.2 Receptor site of Pim1(3R04)  
IV.2.b.iii LIGAND DATABASE PREPARATION 
Database of the collection of ligand molecules which contain various heterocyclic 
rings and different fragments as substitutions, can be used to evaluate the affinity of 
the molecules against different biological targets for their affinity. All molecules were 
sketched in the database had been sketched using maestro 9.1 using the build tool. 
The fragments which had been used were shown in the following figures. 
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Fig IV.3 Fragments used in the database creation 
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Fig IV.4 Some Heterocyclic nucleus used in the study 
 Fig IV.5 Fragments used as a side chain 
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Fig IV.6 Toxicity Filters 
IV.2.b. iv LIGAND PREPARATION 
Ligands built in the database need to be prepared by which we would get ligands of 
very high quality so the task includes are 
• Convert structure format. 
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• Select structures. 
• Add hydrogen atoms.,  
• Remove unwanted molecules,  
• Neutralize charged groups., 
• Generate ionization states , 
• Generate tautomers , 
• Filter structures,  
• Generate alternative chiralities.,  
• Generate low-energy ring conformations,. 
• Remove problematic structures,  
• Optimize the geometries.  
• Convert output file. 
 
IV.2.b.v LIGAND RECEPTOR DOCKING AND PREDICTING 
ACTIVITY 
Docking is been done by using Glide® (an application tool of Maestro 9.1) 
Glide® is designed to assist in high-throughput screening of potential ligands based 
on binding mode and affinity for a given receptor molecule.  
After the preparation of protein, the prepared ligands were docked with the respective 
proteins of Pim1. 
The ligands Database which consist of 1000 molecules which had been already 
prepared by ligprep were first initially docked by using Glide in HTVS (high 
throughput virtual screening) mode and Standard mode (sp). 
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Specifying the Receptor Grid 
To specify the receptor grid for the docking job, we click on Browse in the Receptor 
grid section of the Settings tab to open a file selector and choose a grid file (.grid) or a 
compressed grid archive (.zip). 
Selecting the Docking Precision 
There are three choices of docking . 
• HTVS (high-throughput virtual screening)—High-throughput virtual screening 
(HTVS) docking is intended for the rapid screening of very large numbers of ligands. 
HTVS has much more restricted conformational sampling than SP docking, and 
cannot be used with score-in-place. 
• SP (standard precision)—Standard-precision (SP) docking is appropriate for 
screening ligands of unknown quality in large numbers.  
• XP (extra precision). Extra-precision (XP) docking and scoring is a more powerful 
and discriminating procedure, which takes longer to run than SP. XP is designed to be 
used on ligand poses that have a high score using SP docking. We recommend that 
you run your database through SP docking first, then take the top 10% to 30% of your 
final poses and dock them using XP,  
 
PREDICTING THE ACTIVITY OF TOP MOLECULES 
The top 100 molecules which were found to be top scored in the docking study were 
further refined by predicting the activity which was previously established. 
To calculate activities for the hits based on the QSAR model which was established 
earlier were used to predict the activity of ligands in the top list. At first the 100 
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molecules were taken in the project table and then Catalyst was used to predict the 
activity by taking the common Pharmacophore of Pim1.  
IV.2.b. vi SCAFFOLD IDENTIFICATION 
Scaffold identification is the process of identifying the template commonly occurring 
among the top class of molecules which may able to help us to identify a new class of 
molecules with the best of activity. 
In this the top 35 molecules which we identified after the database screening and 
prediction of activity with the help of 3D QSAR study we were able to identify the 
scaffold  
  
R
 
Fig IV.7 scaffold identified from the docking study 
The synthesis of the following compounds from the scaffhold had been found to be 
synthetically possible to synthesis. These molecules were than tagged as PV1, PV2, 
PV3 and PV4. 
The molecules molecular name was again investigated as a literature review to find 
out the information in NISCAIR. 
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DOCKING OF MOLECULES GOING TO BE SYNTHESIZED 
Docking of selected molecules from the scaffhold is done by XP mode against Pim1 
for evaluating the degree of binding by checking or evaluates the following 
parameters for detailed study with the receptor. 
Table IV.1 
S.NO XP Term Description 
1 GScore 
 
Total GlideScore; sum of XP 
terms 
2 LipophilicEvdW Lipophilic term derived from 
hydrophobic grid potential and fraction of the total protein 
ligandvdW energy 
3 PhobEn Hydrophobic enclosure reward 
4 PhobEnHB Reward for hydrophobically 
packed H-bond 
5 PhobEnPairHB Reward for hydrophobically 
packed correlated H-bonds 
6 HBond ChemScore H-bond pair term 
7 Electro Electrostatic rewards 
8 SiteMap SiteMap ligand/receptor non-Hbonding polar/hydrophobic 
and hydrophobic/hydrophilic complementarity 
terms 
9 LowMW Reward for ligands with low 
molecular weight 
10 Penalties Polar atom burial and desolvation penalties, and penalty 
for intra-ligand contacts 
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11 HBPenal Penalty for ligands with large 
hydrophobic contacts and low H-bond scores 
12 PhobicPenal Penalty for exposed hydrophobic 
ligand groups 
13 RotPenal Rotatable bond penalty 
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                  IV.2.c IN SILICO SCREENING OF DRUG LIKENESS 
The molecules which are to be synthesized need to be investigated for its drug likeness. 
So computational process helps in a vital way to calculate or evaluate the ADME 
parameter beforehand. In silico screening of drug likeness is done by Qikprop. Qikprop 
has 50 characters for accessing the ADME parameters necessary for good drugs. 
QikProp is a quick, accurate, easy-to-use absorption, distribution, metabolism, and 
excretion (ADME) prediction program designed by Professor William L. Jorgensen. 
QikProp predicts physically significant descriptors and pharmaceutically relevant 
properties of organic molecules, either individually or in batches. 
Table IV.2 (50 parameters calculating the drug likeness) 
S.No Property or descriptors Description Range or 
recommended 
values  
1 #stars Number of property or descriptor 
values that fall outside the 95% 
range of similar values for known 
drugs. Outlying descriptors and 
predicted properties are denoted 
with asterisks (*) in the .out file. 
A large number of stars suggest 
that a molecule is less drug-like 
than molecules With few stars.  
 
(combination of all descriptors) 
0 – 5 
2 #amine Number of non-conjugated amine 
groups. 
0 – 1 
3 #amidine Number of amidine and guanidine 
groups. 
0 
4 #acid Number of carboxylic acid 
groups. 
0 – 1 
5 #amide Number of non-conjugated amide 
groups. 
0 – 1 
6 #rotor Number of non-trivial (not CX3), 
non-hindered (not alkene, 
amide,small ring) rotatable bonds. 
0 – 15 
7 #rtvFG Number of reactive functional 0 – 2 
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groups 
8 CNS Predicted central nervous system 
activity on a –2 (inactive) to 
+2 (active) scale. 
–2 (inactive), 
+2 (active) 
9 mol_MW Molecular weight of the molecule 
. 
130.0 – 725.0 
10 SASA Total solvent accessible surface 
area (SASA) in square angstroms  
using a probe with a 1.4 Å radius. 
300.0 – 1000.0 
11 FOSA Hydrophobic component of the 
SASA (saturated carbon and 
attached hydrogen). 
0.0 – 750.0 
12 FISA Hydrophilic component of the 
SASA (SASA on N, O, and H on 
heteroatoms). 
7.0 – 330.0 
13 PISA pi (carbon and attached hydrogen) 
component of the SASA. 
0.0 – 450.0 
14 WPSA Weakly polar component of the 
SASA (halogens, P, and S). 
0.0 – 175.0 
15 volume Total solvent-accessible volume 
in cubic angstroms using a probe 
with a 1.4 Å radius. 
0.0 – 175.0 
16 donorHB Estimated number of hydrogen 
bonds that would be donated by 
the solute to water molecules in an 
aqueous solution. Values are 
averages taken over a number of 
configurations, so they can be 
non-integer. 
0.0 – 6.0 
17 accptHB Estimated number of hydrogen 
bonds that would be accepted by 
the solute from water molecules in 
an aqueous solution. Values are 
averages taken over a number of 
configurations, so they can be 
non-integer. 
2.0 – 20.0 
18 dip^2/V Square of the dipole moment 
divided by the molecular volume. 
This is the key term in the 
Kirkwood-Onsager equation for 
the free energy of solvation of a 
dipole with volume V. 
0.0 – 0.13 
19 ACxDN^.5/SA Index of cohesive interaction in 
solids. 
0.0 – 0.05 
20 glob Globularity descriptor (4 r2) ⁄ 
(SASA)where r is the radius of a 
0.75 – 0.95 
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sphere with a volume equal to the 
molecular volume. Globularity is 
1.0 for a spherical molecule. 
21 QPpolrz Predicted polarizability in cubic 
angstroms. 
13.0 – 70.0 
22 QPlogPC16 Predicted hexadecane/gas 
partition coefficient. 
4.0 – 18.0 
23 QPlogPoct‡ Predicted octanol/gas partition 
coefficient. 
8.0 – 35.0 
24 QPlogPw Predicted water/gas partition 
coefficient. 
4.0 – 45.0 
25 QPlogPo/w Predicted octanol/water partition 
coefficient 
–2.0 – 6.5 
26 QPlogS Predicted aqueous solubility, log 
S. S in mol dm–3 is the 
concentration of the solute in a 
saturated 
solution that is in equilibrium with 
the crystalline solid. 
–6.5 – 0.5 
27 CIQPlogS Conformation-independent 
predicted aqueous solubility, log 
S. S in mol dm–3 is the 
concentration 
of the solute in a saturated 
solution that is in equilibrium with 
the crystalline solid. 
–6.5 – 0.5 
28 QPlogHERG Predicted IC50 value for blockage 
of HERG K+ channels. 
concern below 
–5 
29 QPPCaco Predicted apparent Caco-2 cell 
permeability in nm/sec. Caco-2 
cells are a model for the gutblood 
barrier. QikProp predictions are 
for non-active transport. 
<25 poor, 
>500 great 
30 QPlogBB Predicted brain/blood partition 
coefficient.  
–3.0 – 1.2 
31 QPPMDCK Predicted apparent MDCK cell 
permeability in nm/sec. MDCK 
cells are considered to be a good 
mimic for the blood-brain barrier 
<25 poor, 
>500 great 
32 QPlogKp Predicted skin permeability, log 
Kp. 
–8.0 – –1.0 
33 IP(ev) PM3 calculated ionization 
potential. 
7.9 – 10.5 
34 EA(eV) PM3 calculated electron affinity. –0.9 – 1.7 
35 #metab Number of likely metabolic 
reactions. 
1 – 8 
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36 QPlogKhsa Prediction of binding to human 
serum albumin. 
–1.5 – 1.5 
37 HumanOralAbsorption Predicted qualitative human oral 
absorption: 1, 2, or 3 for low, 
medium, or high.  
1-3 
38 PercentHuman- 
OralAbsorption 
Predicted human oral absorption 
on 0 to 100% scale.The prediction 
is based on a quantitative multiple 
linear regression model. This 
property usually correlates well 
with HumanOral- Absorption, as 
both measure the same property. 
>80% is high 
<25% is poor 
40 SAFluorine Solvent-accessible surface area of 
fluorine atoms. 
0.0 – 100.0 
41 SAamideO Solvent-accessible surface area of 
amide oxygen atoms. 
0.0 – 35.0 
42 PSA Van der Waals surface area of 
polar nitrogen and oxygen atoms. 
7.0 – 200.0 
43 #NandO Number of nitrogen and oxygen 
atoms. 
2 – 15 
44 RuleOfFive Number of violations of 
Lipinski’s rule of five. The rules 
are: mol_MW < 500, QPlogPo/w 
<5, donorHB ≤ 5, accptHB ≤ 10. 
Compunds that satisfy these rules 
are considered drug-like.(The 
“five” refers to the limits, which 
are multiples of 5.) 
maximum is 4 
45 RuleOfThree Number of violations of 
Jorgensen’s rule of three. The 
three rules are: , QPlogS > -5.7, 
QPPCaco > 22 nm/s, # Primary 
Metabolites < 7. 
maximum is 3 
46 #ringatoms Number of atoms in rings.  
47 #in34 Number of atoms in 3- or 4-
membered rings. 
 
48 #in56 Number of atoms in 5- or 6-
membered rings. 
 
49 #noncon number of ring atoms not able to 
form conjugated aromatic systems 
(e.g. sp3 C). 
 
50 #nonHatm Number of heavy atoms 
(nonhydrogen atoms). 
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                                           IV.3 SYNTHESIS 
 
IV.3.i GENERAL SCHME 
       The synthesis involves the two steps first step involve condensation of reactants 
under cooling conditions. Second step involve cyclization of reactant under thermal 
condition.  
General scheme 
Step: 1 
 
O
CH3
+ R
O
C2H5OH
O
R20%NaOH
 
 
Step: 2                                                                                                                                                                                        
         
O
R
H3PO4
C2H5OH
O
O
R
 
    
    Fig IV.8 General Scheme involved in the synthesis of molecules. 
 
IV.3.ii SYNTHESIS 
The syntheses of 4 molecules were carried out in the following way. 
 
PV 1 
Step: 1 
O
CH3
+
O
N
CH3
CH3
20%NaOH
C2H5OH
O
N
CH3
CH3
 
 IV.9.i Reaction involved in the synthesis of PV1 
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     Chalcones were prepared by base catalyzed condensation with 5.85ml of  
acetophenone and 7.45gm of P- dimethyl amino benzaldehyde in ethyl alcohol was 
added to a 20% solution of sodium hydroxide drop wise with stirring. The reaction 
mixture was kept at 0°C for two days then diluted with water and acidified with 2M 
hydrochloric acid. The precipitated chalcone was collected and recrystallised form 
alcohol to yield pure chalcone. Yield  82%. 
Step:2
O
N
CH3
CH3
O
O
N
CH3
CH3
H3PO4
C2H5OH
 
 IV.9.ii Reaction involved in the synthesis of PV1 
 
        Flavanone were prepared by refluxing the corresponding chalcone obtained from 
step1 with phosphoric acid 10 gm in 150ml ethanol for 2 days.concentration of the 
solution and dilution with water gave precipitated product.Recrystallised with ethanol. 
Yield 80%. 
PV2 
Step:1 
O
CH3
+
O
N+
O-
O
20%NaOH
C2H5OH
O
N+
O-
O
 
 IV.10.i Reaction involved in the synthesis of PV2 
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      Chalcones were prepared by base catalyzed condensation with 5.85ml of 
acetophenone and 7.55gm of 3-nitrobenzaldehyde in ethyl alcohol was added to a 
20% solution of sodium hydroxide drop wise with stirring. The reaction mixture was 
kept at 0°C for two days then diluted with water and acidified with 2M hydrochloric 
acid. The precipitated chalcone was collected and recrystallised form alcohol to yield 
pure chalcone. Yield 83%. 
Step:2
O
N+
O-
O
H3PO4
C2H5OH
O
O
N+
O-
O
 
 IV.10.ii Reaction involved in the synthesis of PV2 
 
      Flavanone were prepared by refluxing the corresponding chalcone obtained from 
step1 with phosphoric acid 10 gm in 150ml ethanol for 2 days.concentration of the 
solution and dilution with water gave precipitated product.Recrystallised with ethanol. 
Yield 82%.  
PV3 
Step: 1 
O
CH3
+
O
Cl
20%NaOH
C2H5OH
O
Cl
  
IV.11.i Reaction involved in the synthesis of PV3 
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      Chalcones were prepared by base catalyzed condensation with5.85ml of  
acetophenone and 7gm of P-chlorobenzaldehyde in ethyl alcohol was added to a 20% 
solution of sodium hydroxide drop wise with stirring. The reaction mixture was kept 
at 0°C for two days then diluted with water and acidified with 2M hydrochloric acid. 
The precipitated chalcone was collected and recrystallised form alcohol to yield pure 
chalcone. Yield 85%. 
Step:2 
O
H3PO4
C2H5OH
O
O
Cl
 
 
IV.11.ii Reaction involved in the synthesis of PV3 
 
       Flavanone were prepared by refluxing the corresponding chalcone obtained from 
step1 with phosphoric acid 10 gm in 150ml ethanol for 2 days. concentration of the 
solution and dilution with water gave precipitated product. Recrystallised with 
ethanol. Yield  83%. 
PV4 
Step:1 
O
CH3
+
O
20%NaOH
C2H5OH
O
 
 IV.12.i Reaction involved in the synthesis of PV4 
 
      Chalcones were prepared by base catalyzed condensation with 5.85ml of  
acetophenone and 6.25ml of  cinnamaldehyde in ethyl alcohol was added to a 20% 
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solution of sodium hydroxide drop wise with stirring. The reaction mixture was kept 
at 0°C for two days then diluted with water and acidified with 2M hydrochloric acid. 
The precipitated chalcone was collected and recrystallised form alcohol to yield pure 
chalcone. Yield 88%. 
Step:2 
 
O
H3PO4
C2H5OH
O
O
 
IV.12.ii Reaction involved in the synthesis of PV4 
 
       Flavanone were prepared by refluxing the corresponding chalcone obtained from 
step1 with phosphoric acid 10 gm in 150ml ethanol for 2 days.concentration of the 
solution and dilution with water gave precipitated product.Recrystallised with ethanol. 
Yield 86%. 
V.3.iii RECRYSTALLISATION: 
Ethanol was added to the synthesized compounds and heated so as to dissolve 
completely. The clear solution thus obtained was filtered immediately and set aside 
for cooling. As the temperature decreases crystals were found to appear. The process 
was repeated to obtain a pure crystalline form. 
V.3.iv CHARACTERIZATION AND IDENTIFICATION 
The synthesized compounds were recrystalized and identified by TLC. The melting 
point of the products were found and presented uncorrected. The characterization was 
carried out using sophisticated instruments like IR, NMR and Mass Spectroscopy and 
supplemented with 3D images and characteristic properties through the aid of 
computer software. 
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METHODS INVOLVED 
The synthesized compounds were characterized by  using the following methods: 
MELTING POINT: 
The melting points of the compounds were determined by capillary tube method. The 
temperatures at which the synthesized compounds started losing its crystallinity were 
found and are presented uncorrected. It was observed that the compounds did not 
undergo decomposition during the process. 
THIN LAYER CHROMATOGRAPHY: 
 Precoated aluminum TLC-GF binder was used. Solution of the reactants and products 
in ethanol were prepared. Various mobile phases were tried out of which methanol 
and chloroform was found to be suitable. 
Stationary Phase: Precoated silica gel GF plates 
INFRARED ABSORPTION SPECTROSCOPY115 
Infra red spectroscopy is a valuable tool for determination of organic structure. Most 
important advantage of infra red spectroscopy over other usual methods of structural 
analysis (X-ray diffraction, ESR, etc.,) is that it serves as a introduction tool to 
ascertain the presence and absence of functional group. 
NMR SPECTRA116 
In NMR spectroscopy radiofrequency waves induces transitions between magnetic 
energy levels of nuclei of a molecule. NMR enables us to study the number of 
equivalent protons and their electronic environment. It reveals the different chemical 
environment in which the proton is present and helps us to ascertain the structure of 
molecules. The splitting of the signal is due to the different environment of the 
absorbing proton not with respect to electrons but with respect to the nearby protons. 
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MASS SPECTROSCOPY117 
It is an analytical technique used to establish the molecular structure and molecular 
weight of the analyte under investigation. In mass spectroscopy, the compound under 
investigation is bombarded with a beam of electrons producing ionic fragments of the 
original species. The relative abundance of the fragment ion formed depends on the 
stability of the ion and of the lost radical. The resulting charged particles are then 
separated according to their masses. Mass spectrum is a record of information 
regarding various masses produced and their relative abundances 
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                             IV.4 BIOLOGICAL  EVALUATION 
          IV.4.a ACUTE TOXICITY STUDY 
 This acute toxicity study was designed as per the OECD Guideline for Testing of 
Chemicals, Acute Oral Toxicity (Acute Toxic Class Method), Guideline 423. 
Principle and Purpose: 
 Acute toxicity testing determines the toxicity of a chemical or drug substances after a 
single administration.The main purpose of acute toxicity studies is to evaluate the 
degree of toxicity in a quantitative and qualitative manner with the purpose of 
comparing it with other drug substances (e.g. other drug candidates for the same 
indication). Further, acute toxicity testing provides information about the acute 
toxicity effects of a chemical in a quantitative manner i.e. it generates information 
about mechanism of acute toxicity. 
          The method of determination has changed in the last three decades mainly for 
animal welfare reasons. Producing mortality in animals in order to determine LD50 
(dosis letalis media) is no longer the main purpose of acute toxicity testing. Today, 
acute toxicity focuses on levels of acute tolerance, nature of acute toxicity symptoms 
in the sub-lethal range, and dose levels which cause mortality in few animals i.e. 
quality has replaced quantity. 
          The test is based on stepwise procedure with use of minimum number of 
animals per step; sufficient information is obtained on the acute toxicity of the test 
substance to enable its classification. 
          The substance is administered orally to a group of experimental animals at one 
of the defined dose. The substance is tested sing a stepwise procedure, each step using 
three animals of a single sex (normally females). Absence or presence of compound-
related mortality of the animals dosed at one step will determine the next step, i.e; 
• No further testing is needed. 
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• Dosing of three additional animals, with the same dose 
• Dosing of three additional animals at the next higher or the next 
lower dose levels. 
Experimental Protocol: 
                                 In the present study the oral toxicity of the synthesized 
compounds were performed by acute toxic class method. In this methods the toxicity 
of the synthesized compounds were tested using a procedure, using three mice of a 
single sex. The various concentration of a test drug as per OECD guidelines are as 
follows: 
Group I : Synthesized compound – 5mg 
Group II:  Synthesized compound – 10mg 
Group III: Synthesized compound – 300mg 
Group IV: Synthesized compound – 2000mg 
            The mice is fasted prior to drug administration (food alone withheld not water) 
overnight. After the fasting the animal is weighed and the synthesized compounds 
were administered orally at a dose of 2000mg/kg body weight. Animals were 
observed individually after dosing during the first 30 mins; periodically during the 
first 24 hours with special attention given during the first 24 hours with special 
attention given during the first 4 hours and daily thereafter for a total of 14 days.As no 
mortality was observed with the above dose, a series of doses 250 and 500mg were 
selected for further pharmacological evaluation. The procedure with a starting dose of 
2000mg/kg body weight as per OECD Guidelines is as follows: 
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                                           FigIV.13: Dosing procedure of OECD Guidelines 
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                             IV.4.b IN VITRO ACTIVITY 
 
As per literature (119) the expression of Pim1 was found to be in human colorectal 
cancer cell line (HCT116) cell lines so the synthesized compound in vitro activity was 
performed on the colorectal cancer cell lines. 
 
IV.4.b.i PROCEDURE INVOLVED 
 
The human colorectal carcinoma cell line (HCT116) was obtained from 
National Centre for Cell Science (NCCS), Pune, and grown in Dulbeccos Modified 
Eagles Medium (DMEM) containing 10% fetal bovine serum (FBS). All cells were 
maintained at 370C, 5% CO2, 95% air and 100% relative humidity. Maintenance 
cultures were passaged weekly, and the culture medium was changed twice a week. 
Cell treatment procedure118 
 The monolayer cells were detached with trypsin-ethylenediaminetetraacetic 
acid (EDTA) to make single cell suspensions and viable cells were counted using a 
hemocytometer and diluted with medium with 5% FBS to give final density of 1x105 
cells/ml. one hundred microlitres per well of cell suspension were seeded into 96-well 
plates at plating density of 10,000 cells/well and incubated to allow for cell 
attachment at 370C, 5% CO2, 95% air and 100% relative humidity. After 24 h the cells 
were treated with serial concentrations of the extracts and fractions. They were 
initially dissolved in neat dimethylsulfoxide (DMSO) and further diluted in serum 
free medium to produce five concentrations. One hundred microlitres per well of each 
concentration was added to plates to obtain final concentrations of 100, 10, 1.0 and 
0.1 µM. The final volume in each well was 200 µl and the plates were incubated at 
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370C, 5% CO2, 95% air and 100% relative humidity for 48h. The medium containing 
without samples were served as control. Triplicate was maintained for all 
concentrations. 
MTT assay 
 MTT is a yellow water soluble tetrazolium salt. A mitochondrial enzyme in 
living cells, succinate-dehydrogenase, cleaves the tetrazolium ring, converting the 
MTT to an insoluble purple formazan. Therefore, the amount of formazan produced is 
directly proportional to the number of viable cells. 
 After 48h of incubation, 15µl of MTT (5mg/ml) in phosphate buffered saline 
(PBS) was added to each well and incubated at 370C for 4h. The medium with MTT 
was then flicked off and the formed formazan crystals were solubilized in 100µl of 
DMSO and then measured the absorbance at 570 nm using micro plate reader. The % 
cell inhibition was determined using the following formula and graph was plotted 
between % Cell inhibition and concentration and from this IC50 was calculated. 
% cell Inhibition = 100- Abs (sample)/Abs (control) x100.  
  
 
 
Result and 
Discussion 
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                         V.1. DRUG DESIGN 
V.1.a.PHARMACOPHORE MODELING  
The best hiphop Pharmacophore model indicated the importance of acceptors, ring 
aromatic, hydrophobic aliphatic, hydrophobic aromatic and hydrophobic features 
which were further, confirmed in the hypogen generated models. 
In the hypogen studies 10 hypotheses were generated using the most diverse 24 
molecules from the training set and validated using 91 test molecules. The best 10 
hypothesis consists of two hydrogen bond acceptor, one hydrogen bond donor and 
one hydrophobic feature, their relative distances, angle and other geometric 
parameters. The cost values, correlation and root mean square deviation values are 
given in table. The best hypothesis is characterized by the highest cost difference 
(56.342) lowest RMS error (1.1160) and with correlation (0.88). The fixed cost and 
null cost are 117.449, 173.791. It is evident that as error, weight and configuration 
component are very low, the total Pharmacophore cost is also low, the total 
Pharmacophore cost is also low and close to the fixed cost. Also, as total cost is less 
than the null cost, this model accounts for all the Pharmacophore features and has a 
good predictability power. Figure V.1 shows the best Pharmacophore model aligned 
with the most active and inactive fig V.2 and V.3 represent the best Pharmacophore 
model aligned with the most active and inactive molecules 53 and 91 with IC50 of 
0.001 and 107 respectively. In the fig.V.2 the Pharmacophore features are mapped 
well to the active molecules. On the other hand in fig.V.3 the features of the 
Hydrogen bond donor could not fit well since it is a low active molecule. 
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 Table V.110 Pharmacophore models generated by the HypoGen for pim-1 inhibitors 
Hypothesis Total cost Correlation RMSD ∆cost error features 
      1 
      2 
      3 
      4 
      5 
      6 
      7 
      8 
      9 
     10 
117.449 
120.871 
121.194 
123.076 
125.237 
128.936 
129.403 
130.066 
130.406 
132.659 
0.88652 
0.85746 
0.84753 
0.72759 
0.71593 
0.70900 
0.69560 
0.67955 
0.67388 
0.66926 
1.1160 
1.2397 
1.2745 
1.6459 
1.6751 
1.6949 
1.7241 
1.7609 
1.7735 
1.7825 
56.342 
52.920 
52.597 
50.715 
48.554 
44.855 
44.388 
43.725 
43.385 
41.132 
 
 95.673 
 99.169 
100.207 
113.236 
114.398 
115.080 
116.399 
117.938 
118.449 
118.856 
2HBA,HBD,HY 
2HBA,HBD,HY 
2HBA,HBD,HY 
2HBA,HBD,HY 
2HBA,HBD,HY 
2HBA,HBD,HY 
2HBA,HBD,HY 
2HBA,HBD,HY 
2HBA,HBD,HY 
3HBA,HBD,HY 
* (Null cost -total cost), null cost -173.791, fixed cost- 117.449, for theHypo1 
              weight -1.84, configuration – 19.6775. All cost units are in bits. 
    * A – hydrogen bond acceptor, D – hydrogen bond donor and HY – hydrophobic        
 
 
 
Fig.V.1 HypoGen features with its distance constraints 
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Fig.V.2 Pharmacophore mapped to the most active molecule 
 
 
Fig.V.3 Pharmacophore mapped to the low-active molecule 
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Table.V.2 Experimental and predicted IC50 data of 25 training set molecules against 
HypoGen model.  
a .+ indicates that the predicted IC50 is higher than the experimental IC50; 
-indicates that the predicted IC50 is lower than the experimental IC50; a value of 1 
indicates that the predicted IC50 is equal to the experimental IC5 
b. Activity scale – IC50 < 0.1 µM-+++ (highly active) – IC50 1–10 µM-++ 
(moderately active) – IC50 > 10 µM-+ (low active). 
In the training set, out of eight highly active molecules three are correctly predicted as 
highly active and rest are predicted as moderately active, out of eight medium active 
molecules seven were predicted as moderately active, and in the eight inactive 
molecules, for predicted to be three moderatively active rest were predicted as low 
Compound        
name 
 
Exp.ic50 Predicted.ic50 Error Fit 
value 
Experimental 
cale 
Predicted 
scale 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
0.001 
0.061 
0.130 
0.280 
0.430 
0.6 
0.87 
0.99 
1 
1.6 
3.5 
5.1 
6 
7.5 
8 
10 
11 
19 
25 
38 
52 
69 
78 
110 
0.0021 
0.54 
1 
0.45 
2 
1 
1.6 
1.2 
1.3 
3.1 
1.3 
2.2 
2.4 
2 
1.6 
2.5 
2.4 
3.6 
130 
54 
54 
62 
61 
59 
2.1 
8.8 
7.9 
1.6 
4.5 
1.7 
1.8 
1.2 
1.2 
1.9 
3.7 
-2.3 
-2.5 
-3.8 
-4.9 
-4.1 
-4.4 
-5.2 
5.3 
1.4 
-9.7 
-1.1 
-1.3 
-1.8 
9.25 
6.84 
6.56 
6.92 
6.28 
6.56 
6.37 
6.50 
6.47 
6.08 
5.46 
6.22 
6.19 
6.28 
6.36 
6.18 
6.19 
6.01 
4.45 
4.84 
5.84 
4.77 
4.78 
4.80 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
+++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+++ 
+++ 
++ 
+++ 
++ 
++ 
++ 
++ 
++ 
++ 
+ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
+ 
+ 
++ 
+ 
+ 
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active as shown in table.V.2 was inferred that there is less difference between the 
experimental and the predicted IC50 values and thus the error values are less and the 
fit value are less and the fit values give a good measure of how precisely the defined 
features in the best Pharmacophore fit well with each molecules.   
Model validation and knowledge based screening  
The validity of any Pharmacophore model needs to be ascertained by screening some 
known inhibitors (test set) in order to check how many active molecules are picked in 
the screening process, how their predicted activities are correlated with the 
experimental activities. The best hypothesis was used to screen the 91 pim1 inhibitors 
of the test set which contain high, medium and low active inhibitors, the result gave a 
correlation value of 0.887. Some of the tests set molecules with the experimental 
values are shown in figure V.4 
N
N
O
N
F
N
Chiral
N
N
O
O
Br
N
S
O
O
O
F
F
F
F
N
S
O
O O
O
O
O
O
O
OH
H
H
H
H
N
N
N
N
O
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N
S
N
O
N
N
S
O
O
F
F
N
N
O
O
O
N
S
O
O
Br
2
3
4
5
7
8
9
10
1
6
Exp.IC50:0.001 
.
0.005Pred.IC50:
Exp. IC50:0.005
Pred.IC50:1.1
Exp.IC50:0.073
Pred.IC50: 0.37
Exp.IC50:0.6
Pred.IC50: 1
Exp.IC50:1.1
Pred.IC50:1.6
Exp.IC50:1.77
Pred IC50:15
Exp.IC50:4.79
Pred. IC50:1.1
Exp.IC50:28
Pred.IC50:1.1
Exp.IC50:45
Pred.IC50:0.79
Exp.IC50:78
Pred.IC50:15
  
Fig V.4 Some test set molecules for pim-1 inhibitors along with its experimental and 
Pharmacophore predicted IC50 values. 
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Knowledge based screening 
A total of 1000 molecules were generated based on the knowledge of binding 
interaction of ligands with the protein and also the common features necessary for the 
biological activity of molecules. These molecules were drawn using cerius software 
and were screened for their activities using the developed Pharmacophore models. For 
the final screening of the compounds, the hits were analyzed in the Pharmacophore 
model and the most active hits were identified and their structure are shown in fig. 
glide dock studies were conducted against pim1 inhibitors and designed active 
molecules against the x-ray structure of pim1    
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                          V.1.b DOCKING STUDY 
     As the docking study gives the conformational sample of molecule which would 
bind to the particular protein giving rise to useful information’s aiding our 
possibilities of finding a candidate molecule which could be used for the treatment of 
diseases. So before docking the following steps should be performed as to ensure that 
the testing of each molecule mimics the real binding happening in the body. 
SELECTION AND INVESTIGATION OF PROTEINS 
The Pdb downloaded from the protein databank have the following ID 
PIM1=3R04.The Investigation of protein PDB is very important so as to attain good 
computational results so the tools for analyzing are resolution, R Value, R Free, 
Ramachandran plot. These values were found to be range and the results had been 
shown below 
RESOLUTION  
Resolution is a measure of the quality of the data that has been collected on the crystal 
containing the protein or nucleic acid. (Level of details present in the different ion 
pattern, level of electron density map is calculated) 
Resolution values of the receptors are as following PIM1-1.70 
Resolution should be less than 2.0. 
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R VALUE AND R FREE 
R value is the quality of the atomic model obtained from the crystallographic data of 
particular.                                                                                                                                                   
Receptor/pdb id R Value R Free 
PIM1 
3R04 
0.179 
 
0.206 
 
And the values of PIM1 R value seems to be close 0 and the value of R free is also 
close to R value of their  receptors 
RAMACHANDRAN PLOT 
Ramachandran plot is defined as the phi and psi rotation of the adjacent atoms to 
locate its allowed region, disallowed region etc to know the stability of the protein. 
Since most of the residues available were used in the Pdb of Pim1 is having more 
residues in the allowed region and very less residues in the partially allowed region 
and very little residues in the disallowed region. So the proteins are very good to be 
used shown in figure V.5. 
PROTEIN PREPARATION 
A typical PDB structure file consists of heavy atoms, can contain waters, cofactors, 
and metal ions, and can be multimeric. The structure generally has no information on 
bond orders, topologies, or formal atomic charges. Terminal amide groups can also be 
misaligned, because the X-ray structure analysis cannot usually distinguish between O 
and NH2. Ionization and tautomeric states are also generally unassigned. 
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Pim1 
 
Fig V.5 Ramachandran plot of Pim1 receptor pdb file (3R04) 
      Partially allowed region                 Allowed region        Disallowed region 
. Glide calculations use an all-atom force field for accurate energy evaluation. Thus, 
Glide requires bond orders and ionization states to be properly assigned and performs 
better when side chains are reoriented when necessary and steric clashes are relieved. 
Protein preparation wizard panel is to locate and fix structural defects and prepare 
them for use. 
RECEPTOR GRID GENERATION  
Glide searches for favorable interactions between one or more ligand molecules and a 
receptor molecule, usually a protein. The shape and properties of the receptor are 
represented on a grid by several different sets of fields that provide progressively 
more accurate scoring of the ligand poses. For receptors that adopt more than one 
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conformation on binding, you might want to prepare grids for each conformation, to 
ensure that possible actives are not missed. Glide can, however, handle different 
hydroxyl conformations with a single grid generation. 
Pim1 receptor grid was identified by using this method. 
X= 23.2831Å Y= -36.1077Å Z=2.1563Å 
As the identification of the receptor site of Pim1 grid region has been defined which 
comes as a grid output Zip file in their respective names were generated which were 
used for the docking against the respective set of ligands. 
               
Fig V.6 Receptor grid image of Pim1 receptor (3R04) 
LIGAND DATABASE PREPARATION 
Ligand database is the large collection of large molecules which could possibly 
contain the basic nucleus and large variety of functional groups. These molecules 
were sketched in the Maestro 9.1® by the build tool.  
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Aromatic or Heterocyclic Nucleus and fragments significance 
• Play vital role in the steric occupancy in the receptor site.  
• Hydrophilic or Hydrophobic region mapping necessary for binding against the 
particular receptors. 
• It also play important role in forming Hydrogen bonding by acting as an H 
bond donor or H bond acceptor. 
• Positively or negatively ionizable groups increase the affinity of the ligand 
with the receptor for evoking the desired pharmacological action. 
Toxicity filter significance 
• Usually drugs have chances of producing toxicity so to reduce the chances of 
toxicity we had avoided the functional groups listed in the toxicity filters in 
the fig Molecules in the database need to be prepared so it was preceded to the 
next step. 
LIGAND PREPARATION  
The Schrödinger ligand preparation product LigPrep is designed to prepare high 
quality, all atom 3D structures for large numbers of drug-like molecules, starting with 
2D or 3D structures in SD, Maestro, or SMILES format.  
To give the best results, the structures that were docked must have good 
representations of the actual ligand structures as they would appear in a protein-ligand 
complex. This means that the structures supplied to glide must have three-dimensional 
(3D) structures, realistic bond lengths and bond angles. modified Torsional internal 
coordinates of the ligand during docking, so the rest of the geometric parameters must 
be optimized beforehand, must consist of a single molecule that has no covalent bonds 
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to the receptor, with no accompanying fragments, such as counter ions and solvent 
molecules, must have all their hydrogen’s (filled valences).should have appropriate 
protonation state for physiological pH values etc so the ligands in the database were 
processed by ligprep. 
LIGAND RECEPTOR DOCKING AND PREDICTING ACTIVITY  
The molecules in the database consist of 1000 molecules and which was prepared in 
the earlier steps. Than the molecules were investigated for drug likeness by using 
Qikprop than 960 molecules was filtering and these molecules were docked against 
Pim1.  Top 100 selected were preceded for predicting the activity by using the 3D 
QSAR established in the Pharmacophore modeling. Top 35 Molecules which showed 
very good docking score and predicted activity against Pim1 were selected to identify 
the scaffold.   
SCAFFOLD IDENTIFICATION 
After investigating the results of docking study and predicted activity 
Top 35 molecules were selected and then the common scaffold was identified. 
                                   
O
O
R
R -C6H5N(CH 3)2
R -C6H5NO 2
R
-C6H5Cl
R - C6H5CH=CH
 
Fig V.8 Scaffold identified from the screening The literature review in NISCAIR 
indicted that no work had been done using this molecules.  
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Top molecules identified with the predicted activity and docking score of Pim1 
predicted activity-0.032
glide score-9.40
predicted activity-0.052
glide score-9.80
predicted activity-0.062
glide score-9.1
predicted activity-0.084
glide score-10.12 predic ted ac tiv ity-0.31
glide score-13.50
predic ted ac tiv ity-0.33
glide score-12.86
predicted activity-0.34
glide score-11.09
predicted activity-0.34
glide score-12.46
predicted activity-0.35
glide score-10.45
predicted activity-0.35
glide score-9.10
predicted activity-0.35
glide score-8.70
predicted activity-0.35
glide score-8.83
predicted activity-0.35
glide score-8.60
predicted activity-0.36
glide score-8.44
predicted activity-0.36
glide score-8.16
predicted activity-0.37
glide score-9.22
predicted activity-0.38
glide activity-9.15 predicted activity-0.38
glide score-8.26
predicted acitivity-0.38
glide score-10.14
predicted activity-0.39
glide score-8.38 predicted activity-0.39
glide score-8.19
predicted activity-0.39
glide score-8.97
predicted activity-0.39
glide score-12.7
predicted activity-0.39
glide score-12.21 predicted activity-0.4
glide score-9.64
predicted activity-0.41
glide score-10.10
predicted activity-0.43
glide score-9.84 predicted activity-0.46glide score-10.03 predicted activity-0.45
glide score-9.40 predicted activity-0.46
glide score-8.87
predicted activity-0.33
glide score-8.6
Peridicted activity-0.031
glide score-11.4
 
Fig V.7 Molecules list which had been obtained from screening with their Pim1 
docking and predicted activity score. 
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DOCKING OF MOLECULES TO BE SYNTHESIZED 
Above molecules identified from the scaffolds were docked against Pim 1 and its 
interaction at the particular site were identified 
PV1
 
 Fig V.9 PV1 ligand been docked in the Pim1 receptor 
PV2
 
Fig V.10 PV2 ligand been docked in the Pim1 receptor 
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PV3 
 
Fig V.11 PV3 ligand been docked in the Pim1 receptor 
PV4
 
Fig V.12 ligand been docked in the Pim1 receptor 
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                       XP DOCKING RESULTS OF MOLECULES DOCKED AGAINST Pim1  
                                                                                                                                                                                                    
Table.V.3 Pim 1 XP docking results 
 
 
ligand GScore Lipophi
licEvd
W 
PhobEn PhobEn
HB 
PhobEn
PairHB 
HBond Electro Sitema
p 
LowM
W 
Penalti
es 
HBPen
al 
Phobic
Penel 
RotPen
al 
Pv1 -9.424 -3.64 -1.2 0 0 -0.7 -1.84 -0.35 -0.5 0 0 0 0.10 
Pv3 -8.37 -4.23 -1.35 0 0 -0.7 -0.09 -0.30 -0.5 0 0 0 0.11 
Pv4 -8.84 -3.70 -1.3 0 0 -0.45 -0.06 -0.18 -0.5 0 0 0 0.23 
Pv2 -7.63 -3.55 -1.2 0 0 -0.7 -0.431  0 -0.5 0 0 0 0.10 
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             V.1.c.IN SILICO IVESTICATION OF DRUG LIKINESS  
All the 50 characters calculating varies aspect of ADME was within the range 
assuring that 4 molecules will most probably be very comfortable passing the ADME. 
Table.V.4                                                                                                                                  
 
 
S.No Property or 
descriptors 
Pv1 Pv2 Pv3 Pv4 Range or 
recommended 
values  
1 #stars 0 0 0 0 0 – 5 
2 #amine 0 0 0 0 0 – 1 
3 #amidine 0 0 0 0 0 
4 #acid 0 0 0 0 0 – 1 
5 #amide 0 0 0 0 0 – 1 
6 #rotor 1 1 0 2 0 – 15 
7 #rtvFG 0 0 0 0 0 – 2 
8 CNS 0 1 1 0 –2 (inactive), 
+2 (active) 
9 mol_MW 267.32 269.25 258.7 250.29 130.0 – 725.0 
10 SASA 550.59 504.49 490.813 523.29 300.0 – 1000.0 
11 FOSA 203.49 48.06 48.226 78.176 0.0 – 750.0 
12 FISA 54.089 147.34 50.141 50.161 7.0 – 330.0 
13 PISA 293 307.09 320.8 394.96 0.0 – 450.0 
14 WPSA 0 0 71.64 0 0.0 – 175.0 
15 volume 935.09 846.175 818.68 874.402 0.0 – 175.0 
16 donorHB 0 0 0 0 0.0 – 6.0 
17 accptHB 3.75 3.75 2.75 2.75 2.0 – 20.0 
18 dip^2/V 0 0 0 0 0.0 – 0.13 
19 ACxDN^.5/SA 0 0 0 0 0.0 – 0.05 
20 glob 0.8398 0.875 0.861 0.845 0.75 – 0.95 
21 QPpolrz 33.424 30.02 29.653 31.327 13.0 – 70.0 
22 QPlogPC16 9.282 9.237 8.879 9.384 4.0 – 18.0 
23 QPlogPoct 12.515 13.377 11.631 11.767 8.0 – 35.0 
24 QPlogPw 6.878 7.511 6.157 6.274 4.0 – 45.0 
25 QPlogPo/w 3.538 2.331 3.596 3.776 –2.0 – 6.5 
26 QPlogS -4.525 -3.651 -4.397 -4.368 –6.5 – 0.5 
27 CIQPlogS -3.84 -3.881 -4.121 -3.942 –6.5 – 0.5 
28 QPlogHERG 
 
-5.52 -5.31 -5.296 -5,923 concern below 
 –5 
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S.No Property or 
descriptors 
Pv1 Pv2 Pv3 Pv4 Range or 
recommended 
values  
29 QPPCaco 3040.69 396.817 3314.43 3313.014 <25 poor, 
>500 great 
30 QPlogBB 
 
-0.008 -0.832 0.289 -0.025 –3.0 – 1.2 
31 QPPMDCK 1645.83 182.69 4459.9 1805.718 <25 poor,>500 
great 
32 QPlogKp -1.38 -3.05 -1.314 -0.861 –8.0 – –1.0 
33 IP(ev) 0 0 0 0 7.9 – 10.5 
34 EA(eV) 0 0 0 0 –0.9 – 1.7 
35 #metab 3 4 2 2 1 – 8 
36 QPlogKhsa 0.287 0.029 0.258 -0.336 –1.5 – +1.5 
37 HumanOral 
Absorption 
3 3 3 3 1-3 
38 Percent 
Human- 
Oral 
 Absorption 
100 87.106 100 100 >80% is high 
<25% is poor 
40 SAFluorine 0 0 0 0 0.0 – 100.0 
41 SAamideO 0 0 0 0 0.0 – 35.0 
42 PSA 40.987 80.611 35.77 36.634 7.0 – 200.0 
43 #NandO 3 5 2 2 2 – 15 
44 RuleOfFive 0 0 0 0 maximum is 4 
45 RuleOfThree 0 0 0 0 maximum is 3 
46 #ringatoms 16 16 16 16  
47 #in34 0 0 0 0  
48 #in56 16 16 16 16  
49 #noncon 2 2 2 2  
50 #nonHatm 20 20 18 19  
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                                             V.2. SYNTHESIS  
The compound has synthesized condensation followed by cyclization and 
characterized using following method.                                                           
Table.V.5.PROPERTIES 
 
 IDENTIFICATION AND CHARACTERIZATION 
Thin layer Chromatography 
Stationary phase: recoated silica gel plate 
Mobile Phase        :  
Chloroform: Ethanol (3:1) as developing Solvent system for compound-PV1 
Ethanol: Water (3:1) as developing Solvent system for compounds- PV2. 
Ethanol: Water (4:2) as developing Solvent system for compounds-PV3 
DMSO: Ethanol (3:1) as developing solvent for compound-PV4. 
Location of spots: UV chamber/and Iodine vapors in a tightly closed chamber. 
Properties PV1 PV2 PV3 PV4 
Molecular 
Formula 
C17H17NO2 C15H11NO4 C15H11ClO2 C17H14O2 
Molecular 
Weight 
267.32 269.25 258.69 250.29 
Molar 
Refractivity 
78.92 71.15 69.50 77.41 
Molar Volume 225.9 199.8 199.9 201.9 
Parachor 594.5 546.9 526.9 557.5 
Index of 
Refraction 
1.615 1.630 1.611 1.692 
Surface 
Tension 
47.9 56.1 48.2 58.1 
Density 1.182 1.347 1.293 1.239 
Polarizability 31.28 28.20 27.55 30.68 
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CHARACTERIZATION 
IR SPECTROSCOPY  
IR spectra of synthesized compounds was showing presence of aromatic CH 
stretching vibration between 3100-3000 cm-1 and aromatic C=C stretching at 1450 
cm-1, The carbonyl keto group shows stretching vibration at the region of 1700-1600 
for C=O. The aliphatic CH stretching at 2900-2950 cm-1,C-O-C at 1100-1200cm-1. 
 
MASS SPECTROSCOPY 
All the synthesized compounds exhibited molecular ion peak (M+) of varying 
intensities ascertaining the molecular weights of the compounds 
All the above spectral data confirmed the assigned structure of the synthesized 
compounds. 
 
NMR SPECTROSCOPY 
The 1HNMR spectral data of all the synthesized compounds were in conformity with 
the structure assigned. Compounds showed peak between 3-3.4.2(δppm) which 
indicates the presence of CH2 protons. 
All the compounds showed multiplet signals for the presence of aromatic protons 
between 7.2-7.8 (δppm).PV1 shows peak at 2.8(δppm) which indicates the presence 
of CH3 protons. 
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                            Table.V.6 CHARACTERIZATION AND IDENTIFICATION 
S.NO COMPOUNDS 
ID 
3D STRUCTURE MELTING 
POINT 
MASS 
SPECTRA  
NMR SPECTRA 
         ppm 
IR SPECTRA 
     cm-1 
1 PV1 
 
 
128
º
C 
 
 
267.028 M+ 
ion peak 
 
2.8(CH3) 
3.1(CH2) 
4.2(CH) 
6.7–7.8 (Aromatic H) 
 
 
1744(Keto) 
3001(Ar- CH) 
2901(Ali-CH) 
1080(C-O-C) 
1620(Ar-C=C) 
2 PV2 
 
 
98ºC 
 
 
269.66 M+ 
ion peak 
 
 
3.1(CH2) 
4.2(CH) 
6.7–7.8 (Aromatic H) 
 
                    
1744(Keto) 
3001(Ar- CH) 
2901(Ali-CH) 
1080(C-O-C) 
1620(Ar-C=C) 
3 PV3 
 
 
108
º
C 
 
 
258.27 M+ 
ion peak 
 
 
3.1(CH2) 
4.2(CH) 
6.7–7.8 (Aromatic H) 
 
            
1736(Keto) 
3001(Ar- CH) 
2908(Ali-CH) 
1148(C-O-C) 
1636(Ar-C=C) 
4 PV4 
 
 
95ºC 
 
 
250.08 M+ 
ion peak 
 
 
3.1(CH2),4.2(CH) 
5.3(CH),6.0(CH) 
6.7–7.8 (Aromatic H) 
 
 
             
1744(Keto) 
3001(Ar- CH) 
2901(Ali-CH) 
1080(C-O-C) 
1620(Ar-C=C) 
1450(Ali-C=C 
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                                                              PHYSICAL PROPERTIES 
Table .V.7 
S.NO COMPOUND 
ID 
MOLECULAR 
WEIGHT 
MOLECULAR 
FORMULA 
SOLUBILITY APPEARANCE 
1 PV1 267.32 C17H17NO2 
 
Soluble in Ethanol, 
chloroform 
yellow color crystals  
2 PV2 269.25 
 
C15H11NO4 
 
Soluble in Ethanol, 
Dimethylsulphoxide 
Light brown color crystals 
3 PV3 258.69 
 
C15H11ClO2 
 
Soluble in Ethanol, 
Dimethylsulphoxide 
cream color oily crystals 
4 PV4 250.29 
 
C17H14O2 
 
Soluble in Ethanol, 
Dimethylsulphoxide 
Light yellow color oily 
crystals 
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                  Fig.V.13 IR Spectrum of 2-[4-(dimethylamino)phenyl]-2,3-dihydro-4H-chromen-4-one (PV1) 
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               Fig.V.14 MASS Spectrum of 2-[4-(dimethylamino)phenyl]-2,3-dihydro-4H-chromen-4-one (PV1) 
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                  Fig.V.15 NMR Spectrum of 2-[4-(dimethylamino)phenyl]-2,3-dihydro-4H-chromen-4-one (PV1) 
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                               Fig.V.16 IR Spectrum of 2-(3-nitrophenyl)-2,3-dihydro-4H-chromen-4-one  (PV2) 
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                     Fig.V.17 MASS Spectrum of 2-(3-nitrophenyl)-2,3-dihydro-4H-chromen-4-one  (PV2) 
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                     Fig.V.18 NMR Spectrum of 2-(3-nitrophenyl)-2,3-dihydro-4H-chromen-4-one  (PV2) 
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                        Fig.V.19 IR Spectrum of 2-(4-chlorophenyl)-2,3-dihydro-4H-chromen-4-one (PV3) 
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                        Fig.V.20 MASS Spectrum of 2-(4-chlorophenyl)-2,3-dihydro-4H-chromen-4-one (PV3) 
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                        Fig.V.21 NMR Spectrum of 2-(4-chlorophenyl)-2,3-dihydro-4H-chromen-4-one (PV3) 
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                          Fig.V.22 IR Spectrum of 2-[(Z)-2-phenylethenyl]-2,3-dihydro-4H-chromen-4-one  (PV4) 
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                          Fig.V.23 MASS Spectrum of 2-[(Z)-2-phenylethenyl]-2,3-dihydro-4H-chromen-4-one  (PV4) 
 
Page 108 
 
 
                          Fig.V.24 NMR Spectrum of 2-[(Z)-2-phenylethenyl]-2,3-dihydro-4H-chromen-4-one  (PV4) 
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                                 V.3 BIOLOGICAL ACTIVITY 
            
           V.3.a ACUTE TOXICITY STUDY 
 
• Acute oral toxicity studies were performed according to the OECD guidelines 
423 method. 
• The synthesized compounds were administered initially at a starting dose of 
2000mg/kg body weight in 1% CMC orally and observed for 14 days 
mortality due to acute toxicity. 
• Continuous observation was made atleast twice a day for the effect on 
CNS,ANS, motor activity,salivation, skin coloration and other general signs of 
toxicity were also observed and recorded. 
• Since no sign of toxicity was observed at 2000mg/kg body weight to the group 
animals, the LD50 value of the synthesized compounds(pv1-pv4) were 
expected to exceed 2000mg/kg body weight and represented as class 5 
(2000mg/kg <LD50 > 2500mg/kg) 
• The above studies reveal that all the synthesized compounds proved to be non 
toxic to the animals at test dose level and well tolerated. 
 
 
                                                             RESULTS AND DISCUSSION 
 
Department of Pharmaceutical Chemistry                                                               Page 110 
 
                         V.3.b INVITRO ACTIVITY 
   In vitro study of the synthesized compounds PV1,PV2 and PV3 showed  
activity. The % cell inhibition and IC50 value after 48 hours has also been 
tabulated in the table. The compound PV4 did not show the activity. 
                               Table.V.8 %Cell inhibition of PV1 
S.NO Concentration 
µmol/ml 
                PV1 
% cell ihibition IC50 
µmol/ml 
1 0.1 0.865470  
 
10.59 
2 1.0 18.94514 
3 10 48.64584 
4 100 90.64547 
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                                             Fig.V.25 IC50 value of PV1 
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                                       Table.V.9 %Cell inhibition of PV2                                                                     
2nd
Log10 Concentration
%
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                                                           Fig.V.26 IC50 value of PV2 
 
 
                               
 
S.NO Concentration 
µmol/ml 
                PV1 
% cell ihibition IC50 
µmol/ml 
1 0.1 1.054854  
 
12.80 
2 1.0 17.94875 
3 10 45.92576 
4 100 91.36487 
                                                             RESULTS AND DISCUSSION 
 
Department of Pharmaceutical Chemistry                                                               Page 112 
 
                                  Table.V.10 % Cell inhibition of PV3 
S.NO Concentration 
µmol/ml 
                PV1 
% cell ihibition IC50 
µmol/ml 
1 0.1 2.656545  
 
11.27 
2 1.0 21.65420 
3 10 49.54285 
4 100 92.65466 
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                          Fig.V.27 IC50 value of PV3 
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MEDIA 
 
Fig.V.28 media of  HCT 116 Cell line 
 
PV1 
 
Fig.V.29 Cell Inhibition of PV1 
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PV2 
 
Fig.V.30 Cell Inhibition of PV2 
PV3 
 
                              Fig,V.31 Cell Inhibition of PV2  
  
 
 
Summary 
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                         VI SUMMARY AND CONCLUSION 
• The present work is generating the Pharmacophore hypothesis that can be 
successfully used to predict biological activity. The models were capable of 
predicting the activities. The knowledge of Pharmacophore model was used to 
design and selective of new scaffolds. 
• The selection, investigation and preparation of receptor protein from pdb for 
pim1 and docking of the molecule from the database against prepared Pim 1 
receptor protein was carried out. The best scaffold selected from ligand 
database based, on the Pharmacophore predicted value and docking score 
against pim1 receptor, were chosen for software based ADME studies. 
• The selected scaffold was investigated for the ADME properties. The selected 
molecules having good ADME properties, were selected for synthesis. 
• The synthesis of molecules PV1, PV2, PV3 and PV4 was carried out using the 
identified scaffold. The Synthetic procedure involved condensation followed 
by cyclisation. 
• The synthesized molecules, where characterized by using IR, NMR and 
MASS spectrometry. 
• Acute toxicity studied of synthesized molecules was carried using albino mice. 
The LD50 value of the synthesized compound was above 2000mg/kg. 
• The invitro anticancer activity was done using MTT assay method. The 
synthesized molecules PV1, PV2 and PV3 showed the activity.PV4 showed 
the less activity because hydrophobic feature is not available compare to the 
other compounds. 
 
  
 
 
Future 
scope of 
study 
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                            VII.FUTURE SCOPE OF STUDY  
• The established 3D QSAR and common Pharmacophore which has been   identified 
can be used in the screening of large set of molecules which we want to evaluate for 
Pim 1 inhibitors gaining new molecule for anticancer treatment. 
• As the whole sequence of docking study proposed certain molecules which when 
evaluated showed activity for molecules (PV1, PV2 and PV3) in µM. 
• Since the optimization process also performed, The 4 molecules proposed as per the 
optimization can be synthesized and can further evaluate for biological evaluation 
• These works laid a way to do further studies on these derivatives. 
• The further work carried  as organ based toxicity and  invivo anticancer activity. 
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